GlobeImmune (GBIM) 10-K 16 Mar 16 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2015	Mar. 02, 2016	Jun. 30, 2015
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Trading Symbol	GBIM
Entity Registrant Name	GLOBEIMMUNE INC
Entity Central Index Key	1,245,104
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		5,751,574
Entity Public Float			$ 8,530,639

Balance Sheets

Balance Sheets - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 9,900,722	$ 16,812,459
Other current assets	1,190,053	999,892
Total current assets	11,090,775	17,812,351
Property and equipment, net	209,721	455,768
Other assets	205,645	100,000
Total assets	11,506,141	18,368,119
Current liabilities:
Accounts payable	234,070	572,586
Accrued liabilities	540,787	1,259,332
Deferred revenue	3,450,582	3,340,571
Total current liabilities	4,225,439	5,172,489
Other long-term liabilities	171,500	148,641
Deferred revenue	4,120,802	7,443,498
Total liabilities	$ 8,517,741	$ 12,764,628
Commitments and contingencies
Stockholders' equity (deficit):
Common stock, $0.001 par value. Authorized 100,000,000 shares; issued and outstanding 5,751,574 shares	$ 5,752	$ 5,752
Preferred stock, $0.001 par value. Authorized 5,000,000 shares; issued and outstanding 0 shares
Additional paid-in capital	$ 228,454,293	$ 228,302,479
Accumulated deficit	(225,471,645)	(222,704,740)
Total stockholders' equity	2,988,400	5,603,491
Total liabilities and stockholders' equity	$ 11,506,141	$ 18,368,119

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2015	Dec. 31, 2014	Jul. 08, 2014
Statement Of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000	100,000,000
Common stock, shares issued	5,751,574	5,751,574
Common stock, shares outstanding	5,751,574	5,751,574
Preferred stock, par value	$ 0.001	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Revenue
Collaboration license and services	$ 6,169,634	$ 4,426,561	$ 16,350,132
Milestones			3,000,000
Manufacturing services	288,099	1,539,820	3,168,237
Total revenue	6,457,733	5,966,381	22,518,369
Research and development expenses:
Costs of collaboration license and services	2,359,961	3,452,392	5,856,013
Costs of manufacturing services	288,099	1,539,820	3,168,237
Research and development for proprietary programs	1,835,078	2,221,204	1,860,378
Total research and development	4,483,138	7,213,416	10,884,628
General and administrative	4,554,165	4,276,918	3,174,769
Depreciation and amortization	187,335	295,165	771,280
Total operating expenses	9,224,638	11,785,499	14,830,677
Income (loss) from operations	(2,766,905)	(5,819,118)	7,687,692
Change in value of warrants and put and call options, income (expense)		(1,903,446)	1,842,557
Loss on extinguishment of convertible notes		(4,687,649)
Interest expense		(3,890,662)
Other income		39,949	62,215
Income (loss) before taxes	(2,766,905)	(16,260,926)	9,592,464
Income taxes			115,765
Net income (loss)	(2,766,905)	(16,260,926)	9,476,699
Preferred stock dividends and accretion of offering costs to redemption value		(7,173,901)	(12,885,141)
Net loss applicable to common stockholders	$ (2,766,905)	$ (23,434,827)	$ (3,408,442)
Weighted average shares outstanding-basic and diluted	5,751,574	2,914,690	92,522
Net loss per share attributable to common stockholders-basic and diluted	$ (0.48)	$ (8.04)	$ (36.84)

Statements Stockholders' (Defic

Statements Stockholders' (Deficit) Equity - USD ($)	Total	Common stock	Additional paid-in capital	Accumulated deficit	Redeemable, convertible Series A through E preferred stock
Beginning balance at Dec. 31, 2012	$ (196,124,907)	$ 92		$ (196,124,999)	$ 174,797,249
Beginning balance (shares) at Dec. 31, 2012		92,430			86,570,158
Accretion of offering costs	(526,957)			(526,957)	$ 526,957
Estimated fair value of options for common stock issued for services	27,165		$ 27,165
Accretion of preferred stock to redemption value	(12,358,184)		(211,514)	(12,146,670)	12,358,184
Share-based compensation	182,550		182,550
Exercise of options	$ 1,800	$ 1	1,799
Exercise of options (shares)	382	382
Net income (loss)	$ 9,476,699			9,476,699
Ending balance at Dec. 31, 2013	(199,321,834)	$ 93		(199,321,927)	$ 187,682,390
Ending balance (shares) at Dec. 31, 2013		92,812			86,570,158
Accretion of offering costs	(274,811)			(274,811)	$ 274,811
Estimated fair value of options for common stock issued for services	(40,747)		(40,747)
Accretion of preferred stock to redemption value	(6,899,090)		(52,014)	(6,847,076)	6,899,090
Share-based compensation	89,625		89,625
Exercise of options	$ 37,788	$ 8	37,780
Exercise of options (shares)	8,009	8,009
Conversion of preferred stock to common stock upon initial public offering	$ 194,856,291	$ 2,758	194,853,533		$ (194,856,291)
Conversion of preferred stock to common stock upon initial public offering (shares)		2,757,825			(86,570,158)
Issuance of 1,725,000 shares of common stock (net of offering costs of $2,630,141)	14,619,859	$ 1,725	14,618,134
Issuance of 1,725,000 shares of common stock (net of offering costs of $2,630,141) (shares)		1,725,000
Conversion of convertible notes to common stock	11,679,280	$ 1,168	11,678,112
Conversion of convertible notes to common stock (shares)		1,167,928
Conversion of preferred stock warrants to common stock warrants	7,118,056		7,118,056
Net income (loss)	(16,260,926)			(16,260,926)
Ending balance at Dec. 31, 2014	5,603,491	$ 5,752	228,302,479	(222,704,740)
Ending balance (shares) at Dec. 31, 2014		5,751,574
Estimated fair value of options for common stock issued for services	12,495		12,495
Share-based compensation	139,319		139,319
Net income (loss)	(2,766,905)			(2,766,905)
Ending balance at Dec. 31, 2015	$ 2,988,400	$ 5,752	$ 228,454,293	$ (225,471,645)
Ending balance (shares) at Dec. 31, 2015		5,751,574

Statements Stockholders' (Defi6

Statements Stockholders' (Deficit) Equity (Parenthetical)	12 Months Ended
	Dec. 31, 2014USD ($)
Statement Of Stockholders Equity [Abstract]
Common stock issuance costs	$ 2,630,141

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities:
Net income (loss)	$ (2,766,905)	$ (16,260,926)	$ 9,476,699
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	187,335	295,165	771,280
Share-based compensation	139,319	89,625	182,550
Stock-based payments for services	12,495	(40,747)	27,165
Noncash interest expense from amortization of debt discount and amortization of debt issuance costs		3,562,946	9,268
Noncash interest expense on convertible notes		330,664
Noncash expense (income) from change in valuation of warrants and put and call options		1,903,446	(1,842,557)
Loss on extinguishment of convertible notes		4,687,649
Gain on sale of property and equipment	(159,248)	(91,285)
Changes in operating assets and liabilities:
Increase in other current assets	(295,806)	(98,996)	(14,501)
Decrease in accounts payable	(338,516)	(1,164,035)	(828,883)
Increase (decrease) in accrued liabilities	(718,545)	338,370	(710,820)
Decrease in deferred revenue	(3,212,685)	(3,629,806)	(3,142,740)
Increase in other long-term liabilities	22,859	26,834	4,266
Net cash provided by (used in) operating activities	(7,129,697)	(10,051,096)	3,931,727
Cash flows from investing activities:
Purchase of property and equipment	(35,742)	(294,200)	(12,234)
Sale of property and equipment	253,702	127,354
Net cash provided by (used in) investing activities	217,960	(166,846)	(12,234)
Cash flows from financing activities:
Proceeds from issuance of common stock from stock option exercises		37,788	1,800
Proceeds from issuance of convertible promissory notes		7,500,000
Convertible promissory notes issuance costs		(1,051,487)
Proceeds from issuance of common stock		17,250,000
Common stock issuance costs		(2,630,141)
Net cash provided by financing activities		21,106,160	1,800
Net increase (decrease) in cash and cash equivalents	(6,911,737)	10,888,218	3,921,293
Cash and cash equivalents, beginning of period	16,812,459	5,924,241	2,002,948
Cash and cash equivalents, end of period	$ 9,900,722	16,812,459	5,924,241
Supplemental disclosures of noncash investing and financing activities:
Accretion of preferred stock (dividends)		6,899,090	9,268,638
Accretion of preferred stock (offering costs)		274,811	$ 395,217
Fair value of warrants and put option issued in connection with convertible note payable		6,121,533
Fair value of warrants issued for debt issuance costs		876,778
Non-cash conversion of convertible promissory notes to common stock		8,226,658
Non-cash conversion of preferred stock to common stock		$ 194,856,289

Organization and Nature of Busi

Organization and Nature of Business	12 Months Ended
	Dec. 31, 2015
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization and Nature of Business	(1) Organization and Nature of Business GlobeImmune, Inc. (the Company) was incorporated as Ceres Pharmaceuticals, Ltd. in Colorado on February 10, 1995. The Company changed its name to GlobeImmune, Inc. on May 26, 2001, and reincorporated in Delaware on June 5, 2002. The Company is a biopharmaceutical company focused on developing therapeutic products for cancer and infectious diseases based on our proprietary Tarmogen ® The Company’s operations are subject to certain risks and uncertainties. The risks include negative outcome of clinical trials, inability or delay in completing clinical trials or obtaining regulatory approvals, changing market conditions for products being developed by the Company, more stringent regulatory environment, the need to retain key personnel and protect intellectual property, product liability, and the availability of additional capital financing on terms acceptable to the Company. Because of the numerous risks and uncertainties associated with biopharmaceutical product development and commercialization, the Company is unable to accurately predict the timing or amount of future expenses or when, or if, it will be able to achieve or maintain profitability. Currently, the Company has no products approved for commercial sale, and to date it has not generated any product revenue. The Company has financed its operations primarily through the sale of equity securities, upfront payments pursuant to collaboration agreements, government grants and equipment financing. The size of the Company’s future net losses will depend, in part, on the rate of growth or contraction of expenses and the level and rate of growth, if any, of revenues. The Company’s ability to achieve profitability is dependent on its ability, alone or with others, to complete the development of its product candidates successfully, obtain the required regulatory approvals, manufacture and market its proposed products successfully or have such products manufactured and marketed by others and gain market acceptance for such products. There can be no assurance as to whether or when the Company will achieve profitability.

Liquidity Risks

Liquidity Risks	12 Months Ended
	Dec. 31, 2015
Risks And Uncertainties [Abstract]
Liquidity Risks	(2) The Company has incurred operating losses and has an accumulated deficit as a result of ongoing research and development spending. As of December 31, 2015 and 2014, the Company had an accumulated deficit of $225,471,645 and $222,704,740, respectively. The Company had net losses of $2,766,905 and 16,260,926 and net income of $9,476,699 for the years ended December 31, 2015, 2014 and 2013, respectively, and net cash used in operating activities of $7,129,697 and $10,051,096 and net cash provided by operating activities of $3,931,727 for the years ended December 31, 2015, 2014 and 2013, respectively. The Company anticipates that operating losses and net cash used in operating activities will continue into the foreseeable future. The Company has historically financed its operations primarily through the sale of equity securities, payments pursuant to collaboration agreements, government grants and equipment financing. The Company will continue to be dependent upon such sources of funds until it is able to generate positive cash flows from its operations. The Company believes that its existing cash and cash equivalents as of December 31, 2015 will be sufficient to fund operations through at least January 1, 2017. The Company will be required to fund future operations through the sale of its equity securities, issuance of debt, potential milestone payments, if achieved, and possible future collaboration. There can be no assurance that sufficient funds will be available to the Company when needed from equity or convertible debt financings, that milestone payments will be earned or that future collaboration partnerships will be entered into. If the Company is unable to obtain additional funding from these or other sources when needed, or to the extent needed, it may be necessary to significantly reduce its current rate of spending through further reductions in staff and delaying, scaling back, or stopping certain research and development programs or ceasing operations. Insufficient liquidity may also require the Company to relinquish greater rights to product candidates at an earlier stage of development or on less favorable terms. These events could prevent the Company from successfully executing on its operating plan and could raise substantial doubt about the Company’s ability to continue as a going concern in future periods or cease its operations altogether.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	(3) Summary of Significant Accounting Policies (a) Use of Estimates in the Preparation of Financial Statements The preparation of the financial statements in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) requires management of the Company to make estimates and assumptions relating to the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The most significant estimates in the accompanying financial statements relate to the estimated accrued expenses, the realizability of long-lived assets, the estimated useful lives of property and equipment; the terms of performance under collaboration agreements; the evaluation of loss contingencies; the estimated fair values of warrants for redeemable, convertible preferred stock; and the estimated fair values of share-based awards, including the estimated fair value of the underlying common stock. (b) Initial Public Offering The Company completed an initial public offering (IPO) on July 8, 2014. In the offering, the Company sold 1,725,000 shares of its common stock, including those shares sold pursuant to the underwriter’s exercise of its over-allotment option, at $10.00 per share and raised $17,250,000 before fees and expenses. Upon completion of the offering, all of the Company’s then outstanding preferred stock converted into 2,757,825 shares of its common stock in accordance with the terms of the preferred stock, all of its outstanding preferred stock warrants were reclassified into additional paid-in capital as all of the preferred stock warrants converted into common stock warrants, the 2013 Note and the 2014 Notes, described in note 6, converted into 51,556 and 1,116,372 shares of common stock, respectively, and the warrant issued to the holder of the 2013 Note upon such conversion and the warrants issued to the holders of the 2014 Notes became exercisable for 12,373 and 750,000 shares of common stock, respectively. ( c ) Cash and Cash Equivalents The Company considers all highly liquid instruments purchased with original maturity dates of 90 days or less to be cash equivalents. The Company places its temporary cash investments on deposit with financial institutions it believes to be of high quality. Cash equivalents have maturities of 90 days or less, and their carrying amounts approximate fair value. ( d ) Concentrations of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company has established guidelines to limit its exposure to credit risk by placing investments with high credit quality financial institutions, diversifying its investment portfolio, and making investments with maturities that maintain safety and liquidity. At December 31, 2015 and 2014, the Company’s cash equivalents were with money market funds that invest in securities issued by the U.S. Treasury. ( e ) Property and Equipment Property and equipment are recorded at cost. Maintenance and repairs are charged to expense as incurred, and major additions, replacements, and improvements are capitalized. Depreciation of property and equipment is provided using the straight-line method over the estimated useful lives as follows: Furniture and fixtures 7 years Leasehold improvements Lesser of useful life or life of the lease Laboratory equipment 5 years Computer and office equipment 3 years The cost of assets sold and the related accumulated depreciation are removed from the accounts, and the resulting gain or loss is reflected in the statements of operations in the period in which such sale or disposition occurs. Depreciation and amortization expense for the years ended December 31, 2015, 2014 and 2013 was $187,335, $295,165 and $771,280, respectively. ( f ) Impairment of Long-Lived Assets The Company reviews its long-lived assets, consisting of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable from future undiscounted cash flows. Impairment losses are recorded for the difference between the carrying value and the estimated fair value of the long-lived assets. The Company has not yet generated consistent positive cash flows on an annual basis, and such positive cash flows may not materialize for a significant period in the future. As a result, it is reasonably possible that future evaluations of long-lived assets may result in a conclusion that such assets have been impaired. ( g ) Other Assets As of December 31, 2015 and 2014, other assets, classified as long-term assets in the accompanying balance sheets consisted of a $100,000 security deposit for the lease agreement for the corporate headquarters building and $105,645 of prepayments for the 2016 – 2017 term under Cooperative Research and Development Agreement with the National Cancer Institute. ( h ) Accrued Liabilities The Company makes estimates of its accrued expenses by identifying services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when it has not yet been invoiced or otherwise notified of actual cost. The majority of the Company’s service providers invoice it monthly in arrears for services performed. Examples of estimated accrued expenses include: · fees owed to contract research organizations in connection with preclinical and toxicology studies and clinical trials; · fees owed to investigative sites in connection with clinical trials; · fees owed to contract manufacturers in connection with the production of clinical trial materials; · fees owed for professional services; · property taxes; and · unpaid salaries, wages, and benefits. Accrued liabilities consisted of the following as of: Year ended December 31, 2015 2014 Accrued compensation $ 112,473 578,091 Accrued clinical trial holdbacks — 32,385 Other 428,314 648,856 Total Accrued Liabilities $ 540,787 1,259,332 As of December 31, 2015 and 2014, accrued liabilities included $0 and $32,385 respectively, of holdbacks representing five percent of payments due to entities conducting clinical trials for patient-related fees. The holdbacks will be paid upon completion of the studies and when all data has been received and validated by the Company. ( i ) Deferred Revenue The Company records amounts received but not earned under its collaboration agreements as deferred revenue, which are then classified as either current or long-term in the accompanying balance sheets based on the period during which they are expected to be recognized as revenue. ( j ) Stock-Based Compensation The Company accounts for stock compensation pursuant to ASC Topic 718, Compensation-Stock Compensation The Company accounts for stock options issued to nonemployees in accordance with the provisions of ASC Topic 718 and ASC Subtopic 505-50, Equity-Based Payments to Nonemployees ( k ) Income Taxes The Company accounts for income taxes pursuant to ASC Topic 740, Income Taxes The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. As of December 31, 2015 and 2014, the Company has no unrecognized uncertain tax positions. ( l ) Fair Value of Financial Instruments The carrying amounts of financial instruments, including cash and cash equivalents, restricted cash, accrued liabilities and accounts payable, approximate fair value due to their short-term maturities. The Company accounted for its preferred stock warrants pursuant to ASC Topic 480, Distinguishing Liabilities from Equity The fair value of all the outstanding warrants at December 31, 2014 and July 8, 2014 (the close of our IPO) was $0 and $7,118,054, respectively (see note 7). ( m ) Segment Information The Company operates in one segment, which is the business of developing and commercializing various biopharmaceutical products. ( n ) Research and Development Expenses During 2015, 2014 and 2013, the Company incurred $4,483,138, $7,213,416 and $10,884,628, respectively, in expenses relating to research and development. Research and development costs are expensed as incurred and include costs of collaboration license and services, cost of manufacturing services and research and development for proprietary programs. These costs consist primarily of salaries, supplies, and contract services relating to the development of new products and technologies. The Company contracts with third parties to perform a range of clinical trial activities in the ongoing development of its product candidates. The terms of these agreements vary and may result in uneven payments. Payments under these contracts depend on factors such as the progress toward achievement of certain defined milestones, the successful enrollment of patients, and other events. ( o ) Revenue Recognition In 2015, 2014 and 2013, the Company’s revenue was in the form of upfront fees derived from the discovery, development and commercialization of multiple product candidates based on targeted molecular immunotherapy for the treatment of cancer and infectious diseases and fees for manufacturing services for the Company’s collaborators. The Company’s agreements with its collaborators include fees based on a nonrefundable upfront fee, nonrefundable milestone payments that are triggered upon achievement of specific development or regulatory goals, and future royalties on sales of products that result from the collaboration (see note 8(a) and 8(b)) and fees for manufacturing services. The Company recognizes revenue in accordance with ASC Topic 605 Revenue Recognition The Company evaluates the deliverables under our multiple-element arrangements to determine if they meet the separation criteria in ASC 605-25 and have stand-alone value. The Company allocates revenue to each identified deliverable based on its estimated stand-alone value in relation to the combined estimated stand-alone value of all deliverables, otherwise known as the relative selling price method. The allocated consideration for each deliverable is then recognized over the related obligation period for that deliverable. The Company treats deliverables in an arrangement that do not meet the separation criteria as a single unit of accounting, generally applying applicable revenue recognition guidance for the final deliverable to the combined unit of accounting. The Company recognizes revenue from nonrefundable upfront payments over the estimated term of performance under the related agreements. Since the terms are not specifically identifiable in the agreements, management has estimated the performance terms based on the likelihood and forecasted achievement of development commitments, and other significant commitments of the Company. These advance payments are deferred and recorded as deferred revenue upon receipt, pending recognition, and are classified as a short-term or long-term liability in the accompanying balance sheets. Management evaluates the likely performance period under its collaboration agreements on a periodic basis. If there are changes to the estimated performance periods as a result of the outcome of certain events, the period over which the nonrefundable upfront payments are recognized will be adjusted prospectively. The events that will impact the estimation of the performance period include, among others, the success of the drug candidate programs and the likelihood of the collaborator exercising their options under the collaboration agreement. The Company’s collaboration agreements provide for milestone payments and royalties on future sales. In accordance with the milestone method, each substantive milestone payment is recognized as revenue when the specific milestone is achieved, and royalties are recorded when earned. Revenue recognition related to upfront payments and to milestone payments could be accelerated in the event of early termination of drug programs or, alternatively, decelerated if programs are extended. As such, while changes to such estimates have no impact on its reported cash flows, the Company’s reported revenue is significantly influenced by its estimates of the period over which its obligations are expected to be performed. The Company categorizes its revenues into collaboration license and services, milestones and manufacturing services, substantially all of which come from its collaboration partners. In 2013, the Company received a $4,000,000 Research Project Grant by the National Institute of Allergy and Infectious Diseases, or NIAID, of the National Institute of Health, or NIH, to support the development of Tarmogen immunotherapy product candidates to treat and prevent tuberculosis infection. This work for this grant will be performed and reimbursed over four years. The Company recognizes revenue from this grant as work is performed. At December 31, 2015, the unused portion of the grant was $2.0 million. ( p ) Net Loss per Share Basic net loss per share is computed by dividing net loss applicable to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net loss per share reflects the additional dilution from potential issuances of common stock, such as stock issuable pursuant to the exercise of stock options and warrants. The treasury stock method is used to calculate the potential dilutive effect of these common stock equivalents. Potentially dilutive shares are excluded from the computation of diluted net loss per share when their effect is anti-dilutive. In the periods with net losses, all potentially dilutive securities were anti-dilutive and therefore have been excluded from the computation of diluted net loss per share. The following table summarizes the Company's calculation of net loss per common share attributable to GlobeImmune, Inc. stockholders: Years ended December 31, 2015 2014 2013 Net loss per share: Numerator: Net loss attributable to GlobeImmune, Inc. common stockholders $ (2,766,905 ) (23,434,827 ) (3,408,442 ) Denominator: Weighted-average common shares used in computing net loss per share of common stock - basic and diluted 5,751,574 2,914,690 92,522 Net loss per share of common stock attributable to GlobeImmune, Inc. stockholders - basic and diluted $ (0.48 ) (8.04 ) (36.84 ) The following potentially dilutive securities were excluded from the calculation of diluted net loss per share during each period as the effect was anti-dilutive: Years ended December 31, 2015 2014 2013 Weighted-average convertible preferred stock upon conversion to common stock (as converted basis) * — 1,428,024 2,757,825 Weighted-average warrants to purchase convertible preferred stock as converted basis) * 926,814 411,303 107,057 Outstanding stock options and warrants to purchase common stock at period-end) 248,999 219,180 229,494 Weighted-average convertible promissory note upon conversion to common stock (as converted basis) — 509,947 6,921 Total 1,175,813 2,568,454 3,101,297 * The convertible preferred stock and convertible preferred stock warrants (common stock warrants after the initial public offering) were computed on an as converted basis using a 31.39-to-one conversion ratio for all periods presented. ( q ) Recently Issued Accounting Standards In August 2014, the Financial Accounting Standards Board (the “FASB”) issued ASU 2014-15, “Disclosure of Uncertainties About an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15 requires management to evaluate, at each annual and interim reporting period, whether there are conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern and provide related disclosures. ASU 2014-15 is effective for annual and interim reporting periods beginning January 1, 2017 and is not expected to have a material impact on the Company’s Financial Statements. ASU 2014-09, “Revenue from Contracts with Customer (Topic 606)” requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The guidance will replace most existing revenue recognition guidance when it becomes effective. In November 2015, FASB issued ASU 2015-17, “Balance Sheet Classification of Deferred Taxes”, which eliminates the current requirement to present deferred tax liabilities and assets as current and noncurrent in a classified balance sheet. Instead, entities will be required to classify all deferred tax assets and liabilities as noncurrent. This ASU will be effective for the Company beginning in its first quarter of fiscal year 2018. Early adoption is permitted and is not expected to have a material impact on the Company’s Financial Statements. In February 2016, the FASB issued Accounting Standards Update No. 2016-02, “Leases (Topic 842)”. The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. As an emerging growth company under the Jumpstart Our Business Startups Act of 2012, or JOBS Act, the Company has elected to opt out of the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act. This election is irrevocable. ( r ) Fair Value Measurements In general, asset and liability fair values are determined using the following categories: Level 1 – inputs utilize quoted prices in active markets for identical assets or liabilities. Level 2 – inputs include quoted prices for similar assets or liabilities in active markets, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. Level 3 – inputs are unobservable inputs and include situations where there is little, if any, market activity for the balance sheet items at period end. Pricing inputs are unobservable for the terms and are based on the Company’s own assumptions about the assumptions that a market participant would use. The Company’s financial instruments, including money market investments, warrants, and put options are measured at fair value on a recurring basis. The carrying amount of money market investments as of December 31, 2015 and 2014 approximates fair value based on quoted prices in active markets, or Level 1 inputs. There were no transfers between levels for the years ended December 31, 2015, 2014 and 2013. Assets and liabilities measured at fair value on a recurring basis consisted of the following types of instruments as of December 31, 2015 and 2014: Description December 2015 Quoted prices in active markets for identical assets (Level 1) December 2014 Quoted prices in active markets for identical assets (Level 1) Assets measured at fair value: Money market investments (included in cash and cash equivalents) $ — — 20,173 20,173 A reconciliation of the beginning and ending balances of the Company’s assets and liabilities measured at fair value using significant unobservable, or Level 3, inputs is as follows: Warrants Put Balance of liability at December 31, 2012 (3,301,411 ) — Issuance of warrants in connection with convertible promissory notes (106,087 ) — Issuance of put options in connection with convertible promissory notes — (101,222 ) Income included in net income: Income due to change in fair value 1,842,557 — Balance of liability at December 31, 2013 $ (1,564,941 ) (101,222 ) Issuance of warrants in connection with convertible promissory notes (5,331,175 ) — Issuance of put and call options in connection with convertible promissory notes — (1,667,136 ) Transfer to additional paid-in capital upon completion of initial public offering 7,118,056 3,449,866 Loss included in net loss: Loss due to change in fair value (221,940 ) (1,681,508 ) Balance of liability at December 31, 2014 $ — — Gains (losses) included in net income and loss for the years ended December 31, 2014 and 2013 are reported in change in value of warrants and put and call options.

Cash and Cash Equivalents

Cash and Cash Equivalents	12 Months Ended
	Dec. 31, 2015
Cash And Cash Equivalents [Abstract]
Cash and Cash Equivalents	(4) The following is a summary of cash and cash equivalents and their fair values at: Amortized Unrealized Unrealized Fair market cost gains losses value December 31, 2014 Cash $ 16,792,286 $ — $ — $ 16,792,286 Money market funds 20,173 — — 20,173 Total at December 31, 2014 $ 16,812,459 $ — $ — $ 16,812,459 December 31, 2015 Cash $ 9,900,722 $ — $ — $ 9,900,722 Total at December 31, 2015 $ 9,900,722 $ — $ — $ 9,900,722

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2015
Property Plant And Equipment [Abstract]
Property and Equipment	(5) Property and equipment consist of the following at: Year ended December 31, 2015 2014 Furniture and fixtures 195,420 212,471 Leasehold improvements 7,638,683 7,617,934 Laboratory equipment 1,924,581 3,819,740 Computer and office equipment 250,324 617,264 10,009,008 12,267,409 Less accumulated depreciation (9,799,287 ) (11,811,641 ) 209,721 455,768

Convertible Notes

Convertible Notes	12 Months Ended
	Dec. 31, 2015
Debt Disclosure [Abstract]
Convertible Notes	(6) 2013 Notes In November 2013, we entered into an unsecured convertible promissory note, or the 2013 Note, with a service provider, or the Holder, in settlement of $391,730 of accounts payable. The 2013 Note bore an interest rate of 8.0%, had a term of three years and could be prepaid at any time. The 2013 Note and unpaid accrued interest converted upon the completion of our initial public offering into common stock at a price per share equal to 80% at which our common stock was first offered to the public. Upon completion of our initial public offering, we issued to the holder of the 2013 Note a warrant, equal to 30% of the principal balance of the 2013 Note, to purchase common stock for 10 years with an exercise price equal to the IPO price. We recorded the proceeds from the Note based on the fair value of the warrants ($106,087), put option embedded in the 2013 Note ($101,222) and the 2013 Note and, as such, recorded a debt discount of $207,309 for the allocated value of the warrants and put option. The debt discount was being amortized to interest expense over the term of the 2013 Note. Amortization of $9,268 and $35,749 was recorded in the years ended December 31, 2013 and 2014, respectively, and the unamortized balance of the debt discount was $198,041 as of December 31, 2013. On July 8, 2014 we completed our initial public offering and the 2013 Note converted into 51,556 shares of common stock at $8.00 per share. The carrying amount of the debt for accounting purposes was $352,986, which included accrued interest of $20,718, through the conversion date. We recorded a loss upon the extinguishment of $162,574, equal to the difference between the carrying value and the fair value of the common stock which extinguished the 2013 Note. Upon the conversion of the 2013 Note, pursuant to the 2013 Note’s terms, we issued to the holder of the 2013 Note a warrant exercisable for 12,373 shares of our common stock at an exercise price of $10.00 per share. The estimated fair value of the 2013 Note as of December 31, 2013 approximated its carrying value. 2014 Convertible Notes In January and February 2014, we entered into unsecured convertible notes, the 2014 Notes, with various holders for a total aggregate principal amount of $7,500,000. The 2014 Notes bore an interest rate of 10.0% and had a maturity date of January 31, 2015. Upon completion of our IPO the outstanding principal amount of the 2014 Notes, and any unpaid accrued interest thereon, converted into common stock at a price equal to 70% of the price at which our common stock was first offered to the public. The holders of the 2014 Notes received warrants, equal to 100% of the principal amount of the 2014 Notes to purchase equity securities of us for a five-year period. As a result of our initial public offering, the warrants are exercisable into common stock with an exercise price equal to the price at which our common stock was first offered to the public. We recorded the proceeds from the 2014 Notes based on the fair value of the warrants ($4,454,397), the net of the put and call option embedded in the 2014 Notes ($1,667,136) and the 2014 Notes. As such, we recorded a debt discount of $6,121,533 from the allocated value of the warrants and the put and call options. Amortization of $2,682,285 was recorded in the year ended December 31, 2014. We incurred $1,928,265 of debt issuance costs related to the 2014 Notes. Included in the debt issuance costs were warrants issued to the placement agent that had an estimated value of $876,778 at issuance. Amortization of $844,912 was recorded in the year ended December 31, 2014. On July 8, 2014 we completed an IPO and the 2014 Notes converted into 1,116,372 shares of common stock at a conversion price of $7.00 per share. The carrying amount of the debt for accounting purposes was $6,638,645, which included accrued interest of $314,210, through the conversion date. We recorded a loss upon the extinguishment of $4,525,075, equal to the difference between the carrying value and the fair value of the common stock which extinguished the 2014 Notes. Upon the conversion of the 2014 Notes, pursuant to the terms thereof, we issued to the holders of the 2014 Notes warrants exercisable for 750,000 shares of our common stock at an exercise price of $10.00 per share.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2015
Equity [Abstract]
Stockholders' Equity	(7) ( a ) Initial Public Offering The Company completed an IPO on July 8, 2014. In the offering, the Company sold 1,725,000 shares of its common stock, including those shares sold pursuant to the underwriter’s exercise of its over-allotment option, at $10.00 per share and raised $17,250,000 before fees and expenses. Upon completion of the offering, all of the Company’s then outstanding preferred stock converted into 2,757,825 shares of its common stock in accordance with the terms of the preferred stock, all of its outstanding preferred stock warrants were reclassified into additional paid-in capital as all of the preferred stock warrants converted into common stock warrants, the 2013 Note and the 2014 Notes, described in note 6, converted into 51,556 and 1,116,372 shares of common stock, respectively, and the warrant issued to the holder of the 2013 Note upon such conversion and the warrants issued to the holders of the 2014 Notes became exercisable for 12,373 and 750,000 shares of common stock, respectively. (b) Preferred Stock The Board of Directors may issue Preferred Stock in one or more series and determine the voting power, designation, preferences and any other rights as may be permitted by Delaware General Corporation Law. On July 8, 2014, the Company authorized 5,000,000 shares of preferred stock with a $0.001 par value, of which no shares were issued or outstanding as of December 31, 2015 and 2014, respectively. ( c ) Stock Option Plan During 2002, the Company established a stock option plan (the 2002 Option Plan) providing for the grant of options to purchase common shares to outside directors, executives, certain key employees, and consultants. In April 2014, the Company adopted the 2014 Equity Incentive Plan (2014 EIP) and reserved 393,358 shares of common stock for issuance under the plan. The 2014 EIP is the successor to and continuation of the 2002 Option Plan. The options still outstanding under the 2002 Option Plan will continue to be governed by their existing terms, but any shares subject to outstanding options granted under the 2002 Option Plan that would for any reason subsequently return to the share reserve of the 2002 Option Plan under its terms, will not return to the share reserve of the 2002 Option Plan but will become available for issuance pursuant to awards granted under the 2014 EIP. The number of shares of common stock reserved for issuance under the 2014 EIP will automatically increase on January 1 of each year, starting on January 1, 2015 and continuing through January 1, 2024, by the lesser of 4% of the total number shares of our common stock outstanding on the immediately preceding December 31, or a lesser amount of shares determined by our Board of Directors. In April 2014, the Company adopted the 2014 Employee Stock Purchase Plan (2014 ESPP) and reserved 201,163 shares of common stock for issuance under the plan. The number of shares of common stock reserved for issuance under the 2014 ESPP will automatically increase on January 1 of each year, starting on January 1, 2015 and continuing through January 1, 2024, by the least of (i) 1% of the total number of shares of our common stock outstanding on the immediately preceding December 31; (ii) 402,326 shares of common stock; or (iii) a lesser amount of shares determined by our Board of Directors. As of December 31, 2015, there were 1,071,642 shares authorized, of which 801,556 , were available for future issuance under the 2014 EIP. All of the foregoing shares will become eligible for sale in the public market to the extent permitted by any applicable vesting requirements, the lock-up agreements and Rules 144 and 701 under the Securities Act of 1933, as amended, or the Securities Act. Pursuant to the evergreen provisions of the 2014 ESPP and 2014 EIP, on January 1, 2016, common stock reserved for issuance under the 2014 ESPP automatically increased 57,515 shares to 316,193 shares of common stock and common stock reserved for issuance under the 2014 EIP automatically increased 230,062 shares to 1,301,704 shares of common stock. The Company uses the Black-Scholes option pricing model to estimate the fair value of stock options for employee grants and used the following assumptions to obtain the weighted average grant date fair values: Year Ended December 31, 2015 2014 2013 (a) Risk-free interest rate 1.6% - 1.7% 1.82% — Expected life (in years) 5.5 - 6.0 6.0 — Expected volatility 78.7% - 91.1% 95.7% — (a) There were no stock options granted in 2013. The Company uses the Black-Scholes option pricing model to estimate the fair value of stock options for nonemployee grants and used the following assumptions to estimate fair value each respective year: Year Ended December 31, 2015 2014 2013 Risk-free interest rate 2.0% - 2.2% 2.8% - 3.0% 1.8% - 2.7% Expected life (in years) 10 10 10 Expected volatility 85.3% -85.7% 85.2% -85.4% 82.6% -85.1% The Black-Scholes model requires inputs for risk-free interest rate, dividend yield, volatility, and expected lives of the options. Since the Company has a limited history of stock activity, expected volatility is based on historical data from several public companies similar in size and nature of operations to the Company. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of the grant for a period commensurate with the expected term of the grant. The expected term (without regard to forfeitures) for employee options granted represents the period of time that options granted are expected to be outstanding and is derived from the contractual terms of the options granted. Since the Company has limited employee share option exercises, the expected term was determined using the average of the vesting periods and contractual lives. Prior to the closing of the IPO, to value its common stock for measuring equity based awards, the Company used a combination of the option pricing method and the Probability-Weighted Expected Return Method (“PWERM”) as outlined in the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held-Company Equity Securities Issued as Compensation (AICPA Practice Aid). The option pricing method treats common stock and preferred stock as call options on a subject company’s equity value, with exercise prices based on the liquidation preference of the preferred stock. The model estimates the fair value of each class of securities as a function of the current estimated fair value of the company. The characteristics of each class of stock are examined, including: (1) the conversion ratio; (2) the liquidation preferences assigned to the preferred classes of stock; and (3) the exercise price for all outstanding options and warrants. Under this method, value is allocated to common shares only in circumstances where the total equity value exceeds the liquidation rights associated with the preferred shares. The option-pricing method provides the stockholder the right, but not the obligation, to buy the underlying net assets at a predetermined price or “strike” price. The strike price is determined by analyzing the break points at which value would be allocated to each class of stock, based on the distribution characteristics associated with the equity. The PWERM analyzes the returns afforded to common equity holders under multiple future scenarios. Under the PWERM, share value is based upon the probability-weighted present value of expected future net cash flows (distributions to shareholders), considering each of the possible future events and giving consideration to the rights and preferences of each share class. While this method relies on certain key assumptions, it is best used when the range of possible future outcomes and the corresponding time frames are highly uncertain. Share-based compensation expense is recognized net of estimated pre-vesting forfeitures, which results in recognition of expense on options that are ultimately expected to vest over the expected option term. Forfeitures are estimated at the time of grant using actual historical forfeiture experience and are revised in subsequent periods if actual forfeitures differ from those estimates. As of December 31, 2015 and 2014, the Company’s forfeiture rates were 57.8% and 13.7%, respectively. The following table summarizes common stock option and warrant activities for common stock options and warrants issued to employees, directors, and consultants: Weighted Weighted average Number of average remaining common stock exercise contractual options price term (years) Outstanding at December 31, 2012 376,880 7.87 Exercised (382 ) 4.73 Canceled (147,004 ) 7.82 Outstanding at December 31, 2013 229,494 7.90 Granted 7,279 15.10 Exercised (8,009 ) 4.73 Canceled (9,584 ) 5.86 Outstanding at December 31, 2014 219,180 8.35 Granted 79,603 7.27 Canceled (49,784 ) 9.08 Outstanding at December 31, 2015 248,999 7.86 4.2 Exercisable at December 31, 2015 190,659 8.08 2.7 The following table summarizes information about stock options issued to employees, directors, and consultants that is outstanding at December 31, 2015: Common stock options Common stock options outstanding exercisable Weighted average Weighted remaining average Number contractual Number exercise Exercise price outstanding life (years) exercisable price $ 2.56 6,788 9.53 — $ 2.56 4.73 51,396 0.37 51,396 $ 4.73 5.04 3,995 1.34 3,995 5.04 5.98 59,402 2.17 59,402 5.98 6.93 14,881 3.25 14,881 6.93 7.71 54,246 9.02 2,694 7.71 8.52 3,461 3.75 3,461 8.52 10.07 1,573 5.21 1,573 10.07 12.56 38,369 4.65 38,369 12.56 18.24 14,888 6.24 14,888 18.24 248,999 190,659 The weighted average grant date fair value of options granted during the years ended December 31, 2015 and 2014 was $5.55 and $11.66 per share, respectively. The total grant date fair value of options that vested during 2015, 2014 and 2013 was $83,119, $72,095 and $193,828, respectively. The total intrinsic value, or the difference between the aggregate exercise price and the aggregate fair market price on the day of exercise, of options exercised during the years ended December 31, 2014, and 2013 was $60,940, and $1,560, respectively. The total intrinsic value of options outstanding as of December 31, 2015 and 2014 was $8,205 and $286,299, respectively. The total intrinsic value of options exercisable as of December 31, 2015 and 2014 was $0 and $286,299, respectively. As of December 31, 2015 and 2014, the Company had unrecognized stock-based compensation of $217,191 and $79,145, respectively, related to nonvested stock options, which is expected to be recognized over an estimated weighted average period of 3.0 and 2.2 years, respectively. The Company’s net loss for the years ended December 31, 2015, 2014 and 2013 includes $151,814, $48,878, $209,715 respectively, of stock-based compensation costs. Stock-based compensation included in the Company’s statements of operations for the years ended December 31, 2015, 2014 and 2013 was $3,867, $8,919 and $47,082 in research and development expenses and $147,947, $39,959, $162,633 in general and administrative expenses, respectively. The Company did not recognize a tax benefit from share-based compensation expense because the Company has concluded that it is not more likely than not that the related deferred tax assets, which have been reduced by a full valuation allowance, will be realized. ( d ) Warrants The Company had the following preferred stock warrants that vested upon issuance outstanding as of December 31, 2013 and July 8, 2014 (the close of the IPO). Also included below are the Black-Scholes assumptions used to estimate the fair value of the warrants: Issuance of 2004 Convertible 2006 Convertible Series D Total Total Financing promissory Financing promissory preferred Long- Short- Warrants issued in connection with agreement notes agreement notes stock term term Issue date March June April May May Redeemable, convertible preferred stock underlying the warrant Series A Series B Series B Series C Series C Number of warrants 22,000 411,060 179,372 622,826 2,076,125 Exercise price $ 1.25 1.338 1.338 1.445 1.445 Black-Scholes assumptions as of December 31, 2012 Remaining term (years) 1.2 2.5 3.3 6.4 6.4 Estimated volatility 83 % 86.5 % 85.5 % 92 % 92 % Risk-free interest rate 0.16 % 0.31 % 0.35 % 0.92 % 0.92 % Number of warrants remaining 22,000 411,060 179,372 620,294 2,076,125 Estimated fair value at December 31, 2012 $ 2,837 100,270 52,680 723,631 2,421,993 3,301,411 — Black-Scholes assumptions as of December 31, 2013 Remaining term (years) 0.2 1.5 2.3 5.4 5.4 Estimated volatility 61 % 66.5 % 84.5 % 97 % 97 % Risk-free interest rate 0.07 % 0.24 % 0.52 % 1.58 % 1.58 % Number of warrants remaining 22,000 411,060 179,372 620,294 2,076,125 Estimated fair value at December 31, 2013 $ 13 28,098 32,735 321,603 1,076,405 1,458,841 13 Black-Scholes assumptions as of at July 8, 2014 (close of IPO) Remaining term (years) 1.0 1.8 4.9 4.9 Estimated volatility 70.5 % 68.5 % 82 % 82 % Risk-free interest rate 0.12 % 0.33 % 1.52 % 1.52 % Number of warrants remaining 411,060 179,372 620,294 2,076,125 Estimated fair value at July 8, 2014 (close of IPO) $ (* ) 1,395 2,539 70,381 235,564 309,879 — (*) This warrant expired unexercised on March 18, 2014 In connection with the closing of our IPO, each of the preferred stock warrants automatically converted into a warrant to purchase share of common stock with substantially the same terms, except the term was extended to five years from the close of the IPO for all of the warrants except the Financing agreement warrants. In addition to the warrants above, the Company has recorded the estimated value of the warrants related to the 2013 Note discussed in Note 6 that were ultimately issued upon the completion of the IPO. On July 8, 2014 we completed our IPO and pursuant to the 2013 Note’s terms, we issued to the holder of the Note a warrant exercisable for 12,373 shares of our common stock at an exercise price of $10.00 per share. The estimated fair value as of July 8, 2014 (the close of the IPO) of $104,055 was determined using the Black-Scholes option pricing model, and the following assumptions: 9.4 year remaining term, 91.0% volatility, and a risk-free interest rate of 2.60%. These warrants were classified as liabilities as they were exercisable into redeemable preferred stock until the closing of our IPO on July 8, 2014, at which time they were reclassified as a component of additional paid-in capital. 2014 Notes Warrants As part of the issuance of the 2014 Notes (see Note 6), the Company issued warrants exercisable for 750,000 shares of common stock to the holders of the 2014 Notes with the following terms: · Five year exercise period. · Exercisable into a newly issued series of preferred stock if an initial public offering or subsequent round of equity financing is not completed prior to January 31, 2015. If an initial public offering occurs prior to January 31, 2015, the warrants will be exercisable into common stock. If an initial public offering does not occur and a subsequent round of financing occurs, then the warrants will be exercisable into the equity securities issued in the subsequent round of financing. · The exercise price will be equal to the issuance price of the securities that the warrants are ultimately exercisable into. · The number of shares received upon exercise will be equal to the face value of the 2014 Notes ($7,500,000) plus interest accrued divided by the applicable exercise price. The Company engaged a third-party valuation firm to value the warrants as of the commitment date of the 2014 Notes. Due to the various exercise prices and securities that the warrants are exercisable into, the methodology to value the warrants included a combination of Black-Scholes and Monte Carlo Simulation models that take into consideration probability factors of the various outcomes related to the exercise terms of the warrants. This valuation resulted in an initial valuation of these warrants of $4,454,397. The placement agent of the 2014 Notes also received warrants exercisable for 59,998 shares of common stock as compensation for the placement of the 2014 notes. The warrant coverage received by the placement agent is equal to 10% of the total face value of the 2014 Notes ($750,000) and 10% of the warrant coverage received by the holders of the 2014 Notes ($750,000). The terms of the placement agent warrants are the same as the warrants held by the 2014 Notes holders except for modified warrant coverage and exercise prices on warrants issued related to the face value of the 2014 Notes. The valuation of these warrants was consistent with the above methodology and resulted in an initial valuation of $876,778. These warrants were classified as liabilities as they were exercisable into redeemable preferred stock until the closing of our IPO on July 8, 2014, at which time they were reclassified as a component of additional paid-in capital. Pursuant to ASC Topic 480, the estimated fair value of these warrants are reported as liabilities at their estimated fair value at December 31, 2013, and any changes in fair value during the period are reflected in change in value of warrants and put and call options. ( e ) Common Stock On July 8, 2014, the Company authorized 100,000,000 shares of common stock with a $0.001 par value, of which 5,751,574 shares were issued or outstanding as of December 31, 2015. There are an additional 926,746 shares of common stock issuable upon exercise of outstanding warrants, all of which will be eligible for sale in the public market to the extent permitted by the same restrictions.

Deferred Revenue

Deferred Revenue	12 Months Ended
	Dec. 31, 2015
Deferred Revenue Disclosure [Abstract]
Deferred Revenue	(8) Deferred revenue consisted of the following as of: Year ended December 31, 2015 2014 Celgene $ 7,543,927 10,751,120 Gilead 27,457 32,949 Total deferred revenue 7,571,384 10,784,069 Less: current portion (3,450,582 ) (3,340,571 ) Deferred revenue, long-term $ 4,120,802 7,443,498 (a) Celgene Agreements In May 2009, the Company entered into a Collaboration and Option Agreement with Celgene for the early development of four oncology products and all future oncology drug candidates (which options to future oncology drug candidates were subject to expiration if Celgene did not license one of the initial four named products). Celgene is also a holder of the Company’s common stock. Under the collaboration agreement, Celgene has the option to obtain an exclusive worldwide license to develop and commercialize the product candidates subject to diligence requirements, an up-front development funding fee, milestone payments and royalties. This agreement was amended in June 2011 to replace one of the four named product candidates with another oncology Tarmogen product candidate. The terms of the amendment did not materially modify the agreement as the financial terms and the length of the agreement remained substantially the same. Celgene’s options with respect to the GI-6200 and GI-3000 oncology drug candidate programs will terminate if Celgene does not exercise its options for such programs after the Company delivers certain reports on predefined clinical trials with respect to such drug programs. In March 2013, Celgene declined to exercise its option to the GI-4000 program and returned all rights and development responsibility to the Company. In July 2013, Celgene exercised its option to license the GI-6300 program. As a result of the election to license the GI-6300 program, Celgene has an option to license all future oncology drug candidates developed by the Company on a product by product basis. In July 2015, Celgene exercised its option to license the GI-6200 program and amended the agreement to replace one of the four named product candidates with our GI-6100 program as a drug candidate subject to the Collaboration and Option agreement. The terms of the amendment did not materially modify the agreement as the financial terms and the length of the agreement remained substantially the same. In July 2013, Celgene exercised its option to license the GI-6300 program, including GI- 6301, in exchange for an upfront payment of $9,000,000. As part of that exercise, the Collaboration and Option Agreement was amended as it related to the GI-6300 program. The agreement, as amended, includes (1) a license granted to Celgene as of the date of the exercise of the option to develop and commercialize the GI-6300 product candidates using all of the Company’s related patents, intellectual property and know-how related to these product candidates that existed at the inception of the Collaboration and Option Agreement or any time during the term, (2) the Company supplying drug product for the Phase 2 clinical trial and (3) the Company’s option to perform Phase 2 clinical trials, subject to Celgene’s right to assume performance of those trials. As part of this exercise, certain milestones were modified and adjustments to the royalty rates on net sales were reduced. The modification to the milestones did not materially impact the deliverables that existed at the time of the modification. In July 2015, Celgene exercised its option to license the GI-6200 program, including GI-6207, in exchange for an upfront payment of $1.9 million. Pursuant to the license granted to Celgene as of the date of the exercise of the option to develop and commercialize the GI-6200 product candidates using all of the Company’s related patents, intellectual property and know-how related to these product candidates that existed at the inception of the Collaboration and Option Agreement or any time during the term. As part of this exercise, certain milestones were modified. The modification to the milestones did not materially impact the deliverables that existed at the time of the modification. The Collaboration and Option agreement, as amended including the amendment relating to the GI-6300 program contain the following provisions: · The Company received a $30,000,000 upfront payment to perform research and development and for the option to license products based on the GI-4000, GI-6200, GI-6300 and GI-3000 programs. This payment was made by Celgene in May 2009. · The Company received $1,000,000 in October 2011 and $300,000 in April 2012 from Celgene for additional immunology work for the GI-4000 program. · The Company may receive a total of $85,000,000 in development and regulatory milestones for the GI-6100 program; activities for which the Company is not responsible for completing. · If Celgene exercises its option to the GI-6100 program and these products are commercialized, the Company may also receive up to $60,000,000 in net sales milestones and tiered royalty rates on net sales in the teens on worldwide net sales; activities for which the Company is not responsible for completing. · The Company is eligible to receive a total of $85,000,000 and $60,000,000 in development and regulatory milestone payments for GI-6300 and GI-6200, respectively; activities for which the Company is not responsible for completing. · If GI-6300 or GI-6200 is commercialized by Celgene, the Company may receive up to $60,000,000 in sales milestone payments for each program for which the Company is not responsible for completing. Tiered royalty rates on net sales range from single digits to low double digits · For programs other than GI-6100, GI-6200 and GI-6300, the Company may be eligible to receive up to $101,000,000 in development and regulatory milestone payments for Celgene’s clinical trials, NDA filing and regulatory approvals, up to $60,000,000 in net sales milestone payments for such programs, and tiered royalty rates on net sales in the teens on worldwide net sales; activities for which the Company is not responsible for completing. Upon execution of the May 2009 agreement, the Company estimated that its obligations to perform research and development under the agreement would continue through September 30, 2016 and accordingly were recognizing as revenue the upfront fees received of $31,300,000 as revenue from the date of receipt through September 30, 2016. The Company reviews the term of performance on a quarterly basis and adjusts the revenue recognition period if there are any changes. As of December 31, 2015 and 2014, the unamortized balance of $7,377,906 and $10,656,976, respectively, is expected to be amortized on a straight line basis through March 31, 2018. The Company determined that there were two units of accounting under the July 2013 GI-6300 License Agreement with Celgene: the license to further develop and commercialize GI-6300 and undelivered items related to supplying drug product for the Phase 1 clinical trial and along with the option to perform the Phase 2 clinical trial (subject to Celgene’s right to assume performance of those trials). The Company determined that the license had standalone value based on the fact that the drug candidate has been developed and is currently in a clinical trial, Celgene possesses the knowledge, technology, skills, experience and background necessary for all further development of the drug through commercialization, the Company is not required to perform any additional development work related to GI-6300 and Celgene has the right to sublicense the product. The Company allocated the $9,000,000 of proceeds to the two units of accounting using the relative selling price method. The Company determined the estimated selling price for the license based upon a third party valuation and vendor specific objective evidence for the undelivered items. The allocation resulted in $8,766,881 being allocated to the license and the remaining amount of $233,119 allocated to the undelivered items. The Company recognized $8,766,881 in revenue related to the license in the fourth quarter of 2013 upon the delivery of all intellectual property, reports and documentation for the license to Celgene. Revenue related to the undelivered items of $94,144 at December 31, 2015 and 2014 will be recognized as the services are performed. The current estimated service period for the undelivered items under the GI-6300 License Agreement is through June 2016. The Company determined that there were two units of accounting under the July 2015 GI-6200 License Agreement with Celgene: the license to further develop and commercialize GI-6200 and undelivered items related to supplying drug product for the Phase 2 clinical trial. The Company determined that the license had standalone value based on the fact that the drug candidate has been developed and is currently in a clinical trial, Celgene possesses the knowledge, technology, skills, experience and background necessary for all further development of the drug through commercialization, the Company is not required to perform any additional development work related to GI-6200 and Celgene has the right to sublicense the product. The Company allocated the $1,900,000 of proceeds to the two units of accounting using the relative selling price method. The Company determined the estimated selling price for the license based upon a valuation and vendor specific objective evidence for the undelivered items. The allocation resulted in $1,828,124 being allocated to the license and the remaining amount of $71,876 allocated to the undelivered items. We recognized $1,828,124 in revenue related to the license in the third quarter of 2015 upon the delivery of all intellectual property, reports and documentation for the license to Celgene. Revenue related to the undelivered items of $71,876 at December 31, 2015 will be recognized as the services are performed. The current estimated service period for the undelivered items under the GI-6200 License Agreement is through June 2016. The Company recognized $3,279,069, $3,279,069 and $3,307,338 in revenue related to research and development services and other services during the years ended December 31, 2015, 2014 and 2013, respectively, and license revenue of $1,828,124, $138,975 and $8,766,881 during the years ended December 31, 2015, 2014 and 2013, respectively. Costs incurred under these agreements, included in costs of collaboration licenses and services in the Company’s statement of operations, for the years ended December 31, 2015, 2014 and 2013 were $2,046,970, $2,563,409 and $2,515,055, respectively. To date, the Company has not recognized any revenue in connection with milestone payments, other than the license election noted above, or royalties under this agreement. (b) Gilead Agreement In October 2011, the Company entered into a License and Collaboration Agreement with Gilead, granting Gilead an exclusive license to all hepatitis B Tarmogen product candidates to be developed and commercialized under the collaboration, which includes a license granted at contract outset to develop and commercialize the HBV Tarmogen product candidate GS-4774 using all of the Company’s related patents, intellectual property and know-how related to these product candidates. Under the terms of the agreement, in November 2011 Gilead made a $10,000,000 initial nonrefundable payment to the Company. The Company conducted preclinical development, filed the Investigational New Drug application, or IND, and performed the initial Phase 1a trial in healthy volunteers for the selected HBV Tarmogen. Gilead reimbursed the Company on a periodic basis for the costs and expenses of the Phase 1a clinical trial. Gilead will perform any future clinical development, regulatory, manufacturing and commercialization activities. Gilead activities are subject to commercially reasonable diligence, milestone payments and royalties. Upon satisfaction of certain substantive milestone events for which the Company was partially responsible for completing, the Company received $2,000,000 upon filing an IND for HBV in 2012 and $3,000,000 at the point of commencement of the Phase 1b/2a clinical trial in 2013. The Company is also eligible to receive additional proceeds of up to $130,000,000 in development and regulatory milestones based upon achievement of such milestones by Gilead. If products are commercialized, the Company is eligible to receive tiered royalty rates in the upper single digit to mid-teens and up to $40,000,000 of sales milestone payments based on net sales of the licensed product candidates. The Company is not responsible for the sales efforts. The Company determined there was one unit of accounting under the agreement with Gilead. The non-contingent deliverables under the agreement include: (i) the license to all intellectual property and know-how related to hepatitis B Tarmogen products, (ii) the services to be performed in preclinical development (including the filing of an IND) and in conducting the Phase 1a clinical trial, (iii) participation on the Joint Research and Development Committee, or JRC, and (iv) the requirement to provide consultation to Gilead after Gilead assumes control of development activities. The Company has estimated the performance period for these deliverables to be from October 2011 through 2020. The remaining balance to be recognized as of December 31, 2015 and 2014 was $27,457 and $32,949, respectively. When the agreement was signed, the Company determined that its obligation to supply drug product to Gilead after Gilead assumed control of the development was a contingent deliverable, as the obligation to supply product was contingent on the successful development of the hepatitis B Tarmogen product candidate and the related approval of the IND among other items. Subsequently, Gilead has assumed control of manufacturing. However, a services agreement between the parties also continues to exist. As a result, the services agreement deliverables and the potential incremental fees to be received by the Company will be accounted for only if and when delivery takes place. The Company has determined that the consideration to be received is an appropriate incremental fee and, therefore there is not a significant incremental discount associated with the selling price of the services agreement. The Company determined that the license did not have standalone value at the inception of the agreement. This determination is based on the fact that the license is not sold on a standalone basis, nor could it be resold by Gilead on a standalone basis because the Company has proprietary knowledge, technology, skills, experience and background that no other third party, including Gilead, currently possesses and could not readily obtain at contract inception. Such knowledge, technology, skills, experience and background would be necessary for further development of the hepatitis B Tarmogen product candidate as required under the agreement. The Company is recognizing the initial consideration of $10,000,000 and the amounts it received as reimbursement from Gilead of costs to perform the initial Phase 1a trial on a proportional performance basis over the estimated period of performance to complete the preclinical development and Phase 1a trial services, JRC and consultation services, which is estimated to be from October 2011 through 2020. The Company will measure its progress under the proportional performance method based on hours incurred in proportion to total estimated hours. However, the cumulative revenue recognized under this agreement will be limited to the cumulative cash received to date from Gilead. The Company incurred substantially all of the Company hours during the preclinical development and Phase 1a trial period, which ended in February 2014. The contractual term of the license is on a product and country basis that begins on the effective date of the contract, October 2011, and runs through the expiration of Gilead’s obligation to pay royalties for such product in such country, or until the agreement is terminated. The JRC term is from the effective date of the agreement and terminates at the end of the Research Term, which is the period of time commencing on the date the agreement was signed and ending upon completion of the final clinical study report for the Gilead Phase 1b/2a trial. The consulting term begins upon the conclusion of the Research Term, and the Company estimates the term would end upon commercialization, currently estimated in 2020. The Company recognized $5,492, $221,392 and $4,039,538 in license and services revenue under the arrangement during the years ended December 31, 2015, 2014 and 2013, respectively. The Company also recognized milestone payments of $3,000,000 in 2013. In addition, the Company recognized revenue of $288,099, $1,539,820 and $3,168,237 during the years ended December 31, 2015, 2014 and 2013, respectively, related to manufacturing supply for Phase 2 trials for which Gilead is responsible for performing. Collaboration license and service costs incurred under these agreements, included in costs of collaboration licenses and services in the Company’s statement of operations, for the years ended December 31, 2015, 2014 and 2013 were $312,991, $817,103 and $3,340,958, respectively. Manufacturing services costs incurred under agreements with Gilead, included in costs of manufacturing services in the Company’s statement of operations, for the years ended December 31, 2015, 2014 and 2013 were $288,099, $1,539,820 and $3,168,237, respectively.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2015
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	(9) (a) Contract Commitments The Company has an exclusive license with the University of Colorado (CU) that is used in its research and development activities. This agreement requires the Company make certain development milestone payments, make royalty payments based on sales of approved products, if any, and pay a portion of any consideration received by the Company in exchange for granting a sublicense. Under this agreement, the Company is required to pay to CU certain development milestone payments totaling $150,000 per product candidate beginning upon the filing of an IND through the approval from the FDA and royalties on sales of any products and pay a portion of any consideration the Company receives in exchange for granting a sublicense. After the first commercial sale of the licensed products, each milestone payment shall be credited against future royalties, until the full amount of such milestone payment has been credited in full. In 2015, 2014 and 2013, CU was due $162,335, $5,000 and $450,000, respectively, under this agreement. The Company has entered into a collaboration agreement with the NIH for the preclinical and clinical development of the Company’s proprietary yeast-based Tarmogens expressing tumor-associated antigens as potential vaccines for the prevention and/or therapy of a range of human cancers. The Company has the right to terminate this agreement with 60 days notice. The agreement requires the Company to make annual payments of up to $300,000 based on the clinical trial stage. The Company made payments of $300,000, $300,000 and $300,000 in years ended December 31, 2015, 2014 and 2013, respectively. The Company is party to a series of license agreements with the National Institutes of Health, or NIH, consisting of the NIH MUC1-Oncoprotein license agreement dated July 31, 2015, the NIH MUC1 license agreement dated March 12, 2012, the NIH Brachyury Agreement, dated January 3, 2012 and amended in December 2014, NIH VirusPlus Agreement, dated August 23, 2011 and the NIH CEA Agreement, dated June 12, 2007. Collectively these agreements are referred to as the NIH license agreements. The NIH license agreements grant the Company worldwide, exclusive licenses to make and have made, to use and have used, to sell and have sold, to offer to sell and have offered for sale, and to import and have imported products relating to the use of the Tarmogen immunotherapy platform with certain antigens, other immunotherapy platforms and other intellectual property intended to treat cancer that are covered by licensed patent rights and to practice and have practiced any licensed processes in the licensed fields of use. These license agreements required the Company to make certain noncreditable and nonrefundable initial royalty payments upon signing of each license agreement, make certain milestone payments upon achievement of specified development and commercial milestones, make royalty payments based on sales of approved products, if any, and pay a portion of any consideration the Company receives in exchange for granting a sublicense. The NIH license agreements contain the following provisions: · The NIH has the right to terminate for the Company’s uncured material breach of its obligations under the NIH license agreements, or if the Company becomes insolvent or bankrupt. NIH also has the right to terminate or modify the NIH Agreements if it determines that certain specific events have occurred, such as our failure to achieve any development benchmarks or failure to satisfy unmet health and safety needs, provided that such right is subject to appeal by the Company. · Under the NIH MUC1-Oncoprotein Agreement the Company is required to make royalty advances totaling $500,000 beginning upon the acceptance of the first filing of an application for marketing approval with the FDA through the first commercial sale, and royalty payments once it begins selling products developed under the agreement. · Under the NIH MUC1 Agreement the Company is required to make royalty advances totaling $500,000 beginning upon the acceptance of the first filing of an application for marketing approval with the FDA through the first commercial sale, and royalty payments once it begins selling products developed under the agreement. · Under the NIH Brachyury Agreement the Company is required to make royalty advances totaling $800,000 beginning upon the successful completion of the first Phase 3 clinical study through the first commercial sale, and royalty payments once it begins selling products developed under the agreement. · Under the NIH VirusPlus agreement, the Company is required to make royalty advances totaling $500,000 beginning upon the first filing of an application for marketing approval through the first commercial sale, and royalty payments once it begins selling products developed under the agreement. · Under the NIH CEA agreement, the Company is required to make royalty advances totaling $745,000 beginning upon the filing of an IND through FDA approval, and royalty payments once it begins selling products developed under the agreement. (b) Lease Commitments In April 2014, the Company amended the lease agreement for its office and research facility in Louisville, Colorado. The amendment extended the term five years. The amendment includes escalating rent payments throughout the term. The rent expense related to this lease is recorded monthly on a straight-line basis. Including the lease amendment, future minimum lease payments under the Company’s noncancelable operating leases are as follows as of December 31, 2015: 2016 $ 609,339 2017 627,702 2018 646,475 2019 162,798 $ 2,046,314 During 2015, 2014 and 2013, the Company incurred rental expense of $614,349, $598,315 and $448,664, respectively.

Benefit Plan

Benefit Plan	12 Months Ended
	Dec. 31, 2015
Compensation And Retirement Disclosure [Abstract]
Benefit Plan	(10) The Company has adopted a 401(k) plan that covers substantially all employees who are at least 21 years of age. The plan is a defined contribution plan to which the employees may contribute up to 60% of their compensation. The Company does not match employee contributions.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	( 11) The Company has incurred net losses every year, except for 2013, and expects to incur losses in the future. As a result, the Company did not record a federal income tax provision or benefit during 2015 and 2014. In 2013, the Company recorded a current state tax provision of $115,765 which was recorded due to statutory limitations in the use of state net operating loss carryforwards. A reconciliation of income taxes at the statutory federal income tax rate to net income taxes included in the accompanying statements of operations is as follows: Year Ended December 31, 2015 2014 2013 U.S. federal income tax expense at the statutory rate (34.0 ) % (34.0 ) % 34.0 % State income taxes, net of federal taxes (3.8 ) (1.4 ) 4.1 Available research credits (6.0 ) (2.4 ) (9.3 ) Effect of permanent differences 1.8 22.2 (5.8 ) Change in valuation allowance 42.0 15.6 (21.8 ) Total — % — % 1.2 % Deferred tax assets and liabilities reflect the net tax effects of net operating loss carryforwards, credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and amounts used for income tax purposes. The components of the Company’s deferred tax assets and liabilities are as follows: December 31, 2015 2014 Accrued benefits $ 87,290 93,380 Net operating loss carryforwards 46,660,006 44,142,487 Research credit carryforwards 7,195,372 7,045,830 Deferred revenue 2,839,379 4,138,236 Depreciation of property and equipment 1,128,671 1,351,186 Other 131,766 111,250 Total deferred tax assets 58,042,484 56,882,369 Valuation allowance (58,042,484 ) (56,882,369 ) Deferred tax assets, net of valuation allowance $ — — Based upon the level of historical taxable losses and projections of future taxable losses over the periods in which the deferred tax assets are deductible, management believes it is more likely than not that the Company will not realize the benefits of these deductible differences and accordingly has established a full valuation allowance as of December 31, 2015 and 2014. The increase in valuation allowance was $1,160,115 and $2,540,162 in 2015 and 2014, respectively. Future realization depends on the future earnings of the Company, if any, the timing and amount of which are uncertain as of December 31, 2015. In the future, should management conclude that it is more likely than not that the deferred tax assets are, in fact, at least in part, realizable, the valuation allowance would be reduced to the extent of such realization and recognized as a deferred income tax benefit in the Company’s statements of operations. As of December 31, 2015, the Company had available total federal and state net operating loss carryforwards of approximately $122,800,000, which expire in the years 2023 through 2035, and federal research credit carryforwards of $7,200,000, which expire in the years 2023 through 2035. The utilization of the net operating loss carryforwards and research credits may be limited due to the provisions of Sections 382 and 383 of the Internal Revenue Code if there are significant changes in ownership. Due to the nature of changes of ownership during 2003 and 2007, there will be limitations in the Company’s ability to utilize existing net operating loss carryforwards in future periods. The Company has not completed its analysis of any potential Section 382 ownership changes for the year ended December 31, 2014 and 2015, but the Company anticipates that such an ownership change may have occurred in July 2014 upon the closing of its IPO which will limit its ability to utilize its federal net operating loss carryforwards (and certain other tax attributes) that accrued prior to the IPO. The Company has adopted the authoritative guidance under U.S. GAAP related to the accounting for uncertainty in income taxes, including derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company has evaluated tax positions taken or expected to be taken in the course of preparing the financial statements to determine if the tax positions are “more likely than not” of being sustained by the applicable tax authority. Tax positions not deemed to meet the “more likely than not” threshold would be recorded as a tax benefit or expense in the current year. The Company has concluded that there was no impact related to uncertain tax positions on the results of its operations for the years ended December 31, 2015, 2014 and 2013. The Company classifies interest and penalties arising from the underpayment of income taxes in the statements of operations as income tax expense. As of December 31, 2015 and 2014, the Company has no accrued interest or penalties related to uncertain tax positions. The Company’s conclusions regarding tax positions will be subject to review and may be adjusted at a later date based on factors including, but not limited to, ongoing analyses of tax laws, regulations, and interpretations thereof. The United States is the major tax jurisdiction for the Company, and the earliest tax year subject to examination is 2012, which includes the earliest year for which net operating loss carryforwards are available.

Summary of Significant Accoun19

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Use of Estimates in the Preparation of Financial Statements	(a) Use of Estimates in the Preparation of Financial Statements The preparation of the financial statements in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) requires management of the Company to make estimates and assumptions relating to the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The most significant estimates in the accompanying financial statements relate to the estimated accrued expenses, the realizability of long-lived assets, the estimated useful lives of property and equipment; the terms of performance under collaboration agreements; the evaluation of loss contingencies; the estimated fair values of warrants for redeemable, convertible preferred stock; and the estimated fair values of share-based awards, including the estimated fair value of the underlying common stock.
Initial Public Offering	(b) Initial Public Offering The Company completed an initial public offering (IPO) on July 8, 2014. In the offering, the Company sold 1,725,000 shares of its common stock, including those shares sold pursuant to the underwriter’s exercise of its over-allotment option, at $10.00 per share and raised $17,250,000 before fees and expenses. Upon completion of the offering, all of the Company’s then outstanding preferred stock converted into 2,757,825 shares of its common stock in accordance with the terms of the preferred stock, all of its outstanding preferred stock warrants were reclassified into additional paid-in capital as all of the preferred stock warrants converted into common stock warrants, the 2013 Note and the 2014 Notes, described in note 6, converted into 51,556 and 1,116,372 shares of common stock, respectively, and the warrant issued to the holder of the 2013 Note upon such conversion and the warrants issued to the holders of the 2014 Notes became exercisable for 12,373 and 750,000 shares of common stock, respectively.
Cash and Cash Equivalents	( c ) Cash and Cash Equivalents The Company considers all highly liquid instruments purchased with original maturity dates of 90 days or less to be cash equivalents. The Company places its temporary cash investments on deposit with financial institutions it believes to be of high quality. Cash equivalents have maturities of 90 days or less, and their carrying amounts approximate fair value.
Concentrations of Credit Risk	( d ) Concentrations of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company has established guidelines to limit its exposure to credit risk by placing investments with high credit quality financial institutions, diversifying its investment portfolio, and making investments with maturities that maintain safety and liquidity. At December 31, 2015 and 2014, the Company’s cash equivalents were with money market funds that invest in securities issued by the U.S. Treasury.
Property, Plant and Equipment	( e ) Property and Equipment Property and equipment are recorded at cost. Maintenance and repairs are charged to expense as incurred, and major additions, replacements, and improvements are capitalized. Depreciation of property and equipment is provided using the straight-line method over the estimated useful lives as follows: Furniture and fixtures 7 years Leasehold improvements Lesser of useful life or life of the lease Laboratory equipment 5 years Computer and office equipment 3 years The cost of assets sold and the related accumulated depreciation are removed from the accounts, and the resulting gain or loss is reflected in the statements of operations in the period in which such sale or disposition occurs. Depreciation and amortization expense for the years ended December 31, 2015, 2014 and 2013 was $187,335, $295,165 and $771,280, respectively.
Impairment of Long - Lived Assets	( f ) Impairment of Long-Lived Assets The Company reviews its long-lived assets, consisting of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable from future undiscounted cash flows. Impairment losses are recorded for the difference between the carrying value and the estimated fair value of the long-lived assets. The Company has not yet generated consistent positive cash flows on an annual basis, and such positive cash flows may not materialize for a significant period in the future. As a result, it is reasonably possible that future evaluations of long-lived assets may result in a conclusion that such assets have been impaired.
Other Assets	( g ) Other Assets As of December 31, 2015 and 2014, other assets, classified as long-term assets in the accompanying balance sheets consisted of a $100,000 security deposit for the lease agreement for the corporate headquarters building and $105,645 of prepayments for the 2016 – 2017 term under Cooperative Research and Development Agreement with the National Cancer Institute.
Accrued Liabilities	( h ) Accrued Liabilities The Company makes estimates of its accrued expenses by identifying services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when it has not yet been invoiced or otherwise notified of actual cost. The majority of the Company’s service providers invoice it monthly in arrears for services performed. Examples of estimated accrued expenses include: · fees owed to contract research organizations in connection with preclinical and toxicology studies and clinical trials; · fees owed to investigative sites in connection with clinical trials; · fees owed to contract manufacturers in connection with the production of clinical trial materials; · fees owed for professional services; · property taxes; and · unpaid salaries, wages, and benefits. Accrued liabilities consisted of the following as of: Year ended December 31, 2015 2014 Accrued compensation $ 112,473 578,091 Accrued clinical trial holdbacks — 32,385 Other 428,314 648,856 Total Accrued Liabilities $ 540,787 1,259,332 As of December 31, 2015 and 2014, accrued liabilities included $0 and $32,385 respectively, of holdbacks representing five percent of payments due to entities conducting clinical trials for patient-related fees. The holdbacks will be paid upon completion of the studies and when all data has been received and validated by the Company.
Deferred Revenue	( i ) Deferred Revenue The Company records amounts received but not earned under its collaboration agreements as deferred revenue, which are then classified as either current or long-term in the accompanying balance sheets based on the period during which they are expected to be recognized as revenue.
Stock Based Compensation	( j ) Stock-Based Compensation The Company accounts for stock compensation pursuant to ASC Topic 718, Compensation-Stock Compensation The Company accounts for stock options issued to nonemployees in accordance with the provisions of ASC Topic 718 and ASC Subtopic 505-50, Equity-Based Payments to Nonemployees
Income Taxes	( k ) Income Taxes The Company accounts for income taxes pursuant to ASC Topic 740, Income Taxes The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. As of December 31, 2015 and 2014, the Company has no unrecognized uncertain tax positions.
Fair Value of Financial Instruments	( l ) Fair Value of Financial Instruments The carrying amounts of financial instruments, including cash and cash equivalents, restricted cash, accrued liabilities and accounts payable, approximate fair value due to their short-term maturities. The Company accounted for its preferred stock warrants pursuant to ASC Topic 480, Distinguishing Liabilities from Equity The fair value of all the outstanding warrants at December 31, 2014 and July 8, 2014 (the close of our IPO) was $0 and $7,118,054, respectively (see note 7).
Segment Information	( m ) Segment Information The Company operates in one segment, which is the business of developing and commercializing various biopharmaceutical products.
Research and Development Expenses	( n ) Research and Development Expenses During 2015, 2014 and 2013, the Company incurred $4,483,138, $7,213,416 and $10,884,628, respectively, in expenses relating to research and development. Research and development costs are expensed as incurred and include costs of collaboration license and services, cost of manufacturing services and research and development for proprietary programs. These costs consist primarily of salaries, supplies, and contract services relating to the development of new products and technologies. The Company contracts with third parties to perform a range of clinical trial activities in the ongoing development of its product candidates. The terms of these agreements vary and may result in uneven payments. Payments under these contracts depend on factors such as the progress toward achievement of certain defined milestones, the successful enrollment of patients, and other events.
Revenue Recognition	( o ) Revenue Recognition In 2015, 2014 and 2013, the Company’s revenue was in the form of upfront fees derived from the discovery, development and commercialization of multiple product candidates based on targeted molecular immunotherapy for the treatment of cancer and infectious diseases and fees for manufacturing services for the Company’s collaborators. The Company’s agreements with its collaborators include fees based on a nonrefundable upfront fee, nonrefundable milestone payments that are triggered upon achievement of specific development or regulatory goals, and future royalties on sales of products that result from the collaboration (see note 8(a) and 8(b)) and fees for manufacturing services. The Company recognizes revenue in accordance with ASC Topic 605 Revenue Recognition The Company evaluates the deliverables under our multiple-element arrangements to determine if they meet the separation criteria in ASC 605-25 and have stand-alone value. The Company allocates revenue to each identified deliverable based on its estimated stand-alone value in relation to the combined estimated stand-alone value of all deliverables, otherwise known as the relative selling price method. The allocated consideration for each deliverable is then recognized over the related obligation period for that deliverable. The Company treats deliverables in an arrangement that do not meet the separation criteria as a single unit of accounting, generally applying applicable revenue recognition guidance for the final deliverable to the combined unit of accounting. The Company recognizes revenue from nonrefundable upfront payments over the estimated term of performance under the related agreements. Since the terms are not specifically identifiable in the agreements, management has estimated the performance terms based on the likelihood and forecasted achievement of development commitments, and other significant commitments of the Company. These advance payments are deferred and recorded as deferred revenue upon receipt, pending recognition, and are classified as a short-term or long-term liability in the accompanying balance sheets. Management evaluates the likely performance period under its collaboration agreements on a periodic basis. If there are changes to the estimated performance periods as a result of the outcome of certain events, the period over which the nonrefundable upfront payments are recognized will be adjusted prospectively. The events that will impact the estimation of the performance period include, among others, the success of the drug candidate programs and the likelihood of the collaborator exercising their options under the collaboration agreement. The Company’s collaboration agreements provide for milestone payments and royalties on future sales. In accordance with the milestone method, each substantive milestone payment is recognized as revenue when the specific milestone is achieved, and royalties are recorded when earned. Revenue recognition related to upfront payments and to milestone payments could be accelerated in the event of early termination of drug programs or, alternatively, decelerated if programs are extended. As such, while changes to such estimates have no impact on its reported cash flows, the Company’s reported revenue is significantly influenced by its estimates of the period over which its obligations are expected to be performed. The Company categorizes its revenues into collaboration license and services, milestones and manufacturing services, substantially all of which come from its collaboration partners. In 2013, the Company received a $4,000,000 Research Project Grant by the National Institute of Allergy and Infectious Diseases, or NIAID, of the National Institute of Health, or NIH, to support the development of Tarmogen immunotherapy product candidates to treat and prevent tuberculosis infection. This work for this grant will be performed and reimbursed over four years. The Company recognizes revenue from this grant as work is performed. At December 31, 2015, the unused portion of the grant was $2.0 million.
Net Loss Per Share	( p ) Net Loss per Share Basic net loss per share is computed by dividing net loss applicable to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net loss per share reflects the additional dilution from potential issuances of common stock, such as stock issuable pursuant to the exercise of stock options and warrants. The treasury stock method is used to calculate the potential dilutive effect of these common stock equivalents. Potentially dilutive shares are excluded from the computation of diluted net loss per share when their effect is anti-dilutive. In the periods with net losses, all potentially dilutive securities were anti-dilutive and therefore have been excluded from the computation of diluted net loss per share. The following table summarizes the Company's calculation of net loss per common share attributable to GlobeImmune, Inc. stockholders: Years ended December 31, 2015 2014 2013 Net loss per share: Numerator: Net loss attributable to GlobeImmune, Inc. common stockholders $ (2,766,905 ) (23,434,827 ) (3,408,442 ) Denominator: Weighted-average common shares used in computing net loss per share of common stock - basic and diluted 5,751,574 2,914,690 92,522 Net loss per share of common stock attributable to GlobeImmune, Inc. stockholders - basic and diluted $ (0.48 ) (8.04 ) (36.84 ) The following potentially dilutive securities were excluded from the calculation of diluted net loss per share during each period as the effect was anti-dilutive: Years ended December 31, 2015 2014 2013 Weighted-average convertible preferred stock upon conversion to common stock (as converted basis) * — 1,428,024 2,757,825 Weighted-average warrants to purchase convertible preferred stock as converted basis) * 926,814 411,303 107,057 Outstanding stock options and warrants to purchase common stock at period-end) 248,999 219,180 229,494 Weighted-average convertible promissory note upon conversion to common stock (as converted basis) — 509,947 6,921 Total 1,175,813 2,568,454 3,101,297 * The convertible preferred stock and convertible preferred stock warrants (common stock warrants after the initial public offering) were computed on an as converted basis using a 31.39-to-one conversion ratio for all periods presented.
Recently Issued Accounting Standards	( q ) Recently Issued Accounting Standards In August 2014, the Financial Accounting Standards Board (the “FASB”) issued ASU 2014-15, “Disclosure of Uncertainties About an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15 requires management to evaluate, at each annual and interim reporting period, whether there are conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern and provide related disclosures. ASU 2014-15 is effective for annual and interim reporting periods beginning January 1, 2017 and is not expected to have a material impact on the Company’s Financial Statements. ASU 2014-09, “Revenue from Contracts with Customer (Topic 606)” requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The guidance will replace most existing revenue recognition guidance when it becomes effective. In November 2015, FASB issued ASU 2015-17, “Balance Sheet Classification of Deferred Taxes”, which eliminates the current requirement to present deferred tax liabilities and assets as current and noncurrent in a classified balance sheet. Instead, entities will be required to classify all deferred tax assets and liabilities as noncurrent. This ASU will be effective for the Company beginning in its first quarter of fiscal year 2018. Early adoption is permitted and is not expected to have a material impact on the Company’s Financial Statements. In February 2016, the FASB issued Accounting Standards Update No. 2016-02, “Leases (Topic 842)”. The new standard establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. As an emerging growth company under the Jumpstart Our Business Startups Act of 2012, or JOBS Act, the Company has elected to opt out of the extended transition period for complying with new or revised accounting standards pursuant to Section 107(b) of the JOBS Act. This election is irrevocable.
Fair Value Measurements	( r ) Fair Value Measurements In general, asset and liability fair values are determined using the following categories: Level 1 – inputs utilize quoted prices in active markets for identical assets or liabilities. Level 2 – inputs include quoted prices for similar assets or liabilities in active markets, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. Level 3 – inputs are unobservable inputs and include situations where there is little, if any, market activity for the balance sheet items at period end. Pricing inputs are unobservable for the terms and are based on the Company’s own assumptions about the assumptions that a market participant would use. The Company’s financial instruments, including money market investments, warrants, and put options are measured at fair value on a recurring basis. The carrying amount of money market investments as of December 31, 2015 and 2014 approximates fair value based on quoted prices in active markets, or Level 1 inputs. There were no transfers between levels for the years ended December 31, 2015, 2014 and 2013. Assets and liabilities measured at fair value on a recurring basis consisted of the following types of instruments as of December 31, 2015 and 2014: Description December 2015 Quoted prices in active markets for identical assets (Level 1) December 2014 Quoted prices in active markets for identical assets (Level 1) Assets measured at fair value: Money market investments (included in cash and cash equivalents) $ — — 20,173 20,173 A reconciliation of the beginning and ending balances of the Company’s assets and liabilities measured at fair value using significant unobservable, or Level 3, inputs is as follows: Warrants Put Balance of liability at December 31, 2012 (3,301,411 ) — Issuance of warrants in connection with convertible promissory notes (106,087 ) — Issuance of put options in connection with convertible promissory notes — (101,222 ) Income included in net income: Income due to change in fair value 1,842,557 — Balance of liability at December 31, 2013 $ (1,564,941 ) (101,222 ) Issuance of warrants in connection with convertible promissory notes (5,331,175 ) — Issuance of put and call options in connection with convertible promissory notes — (1,667,136 ) Transfer to additional paid-in capital upon completion of initial public offering 7,118,056 3,449,866 Loss included in net loss: Loss due to change in fair value (221,940 ) (1,681,508 ) Balance of liability at December 31, 2014 $ — — Gains (losses) included in net income and loss for the years ended December 31, 2014 and 2013 are reported in change in value of warrants and put and call options.

Summary of Significant Accoun20

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Property and Equipment, Schedule of Useful Lives	Depreciation of property and equipment is provided using the straight-line method over the estimated useful lives as follows: Furniture and fixtures 7 years Leasehold improvements Lesser of useful life or life of the lease Laboratory equipment 5 years Computer and office equipment 3 years
Schedule of Accrued Liabilities	Accrued liabilities consisted of the following as of: Year ended December 31, 2015 2014 Accrued compensation $ 112,473 578,091 Accrued clinical trial holdbacks — 32,385 Other 428,314 648,856 Total Accrued Liabilities $ 540,787 1,259,332
Schedule of Net Loss Per Share, Basic and Diluted	The following table summarizes the Company's calculation of net loss per common share attributable to GlobeImmune, Inc. stockholders: Years ended December 31, 2015 2014 2013 Net loss per share: Numerator: Net loss attributable to GlobeImmune, Inc. common stockholders $ (2,766,905 ) (23,434,827 ) (3,408,442 ) Denominator: Weighted-average common shares used in computing net loss per share of common stock - basic and diluted 5,751,574 2,914,690 92,522 Net loss per share of common stock attributable to GlobeImmune, Inc. stockholders - basic and diluted $ (0.48 ) (8.04 ) (36.84 )
Schedule of Antidilutive Securities Excluded from Calculation of Diluted Net Loss Per Share	The following potentially dilutive securities were excluded from the calculation of diluted net loss per share during each period as the effect was anti-dilutive: Years ended December 31, 2015 2014 2013 Weighted-average convertible preferred stock upon conversion to common stock (as converted basis) * — 1,428,024 2,757,825 Weighted-average warrants to purchase convertible preferred stock as converted basis) * 926,814 411,303 107,057 Outstanding stock options and warrants to purchase common stock at period-end) 248,999 219,180 229,494 Weighted-average convertible promissory note upon conversion to common stock (as converted basis) — 509,947 6,921 Total 1,175,813 2,568,454 3,101,297 * The convertible preferred stock and convertible preferred stock warrants (common stock warrants after the initial public offering) were computed on an as converted basis using a 31.39-to-one conversion ratio for all periods presented.
Fair Value Measurements, Recurring and Nonrecurring	Assets and liabilities measured at fair value on a recurring basis consisted of the following types of instruments as of December 31, 2015 and 2014: Description December 2015 Quoted prices in active markets for identical assets (Level 1) December 2014 Quoted prices in active markets for identical assets (Level 1) Assets measured at fair value: Money market investments (included in cash and cash equivalents) $ — — 20,173 20,173
Reconciliation of Assets and Liabilities Measured at Fair Value Using Significant Unobservable Level 3 Inputs	A reconciliation of the beginning and ending balances of the Company’s assets and liabilities measured at fair value using significant unobservable, or Level 3, inputs is as follows: Warrants Put Balance of liability at December 31, 2012 (3,301,411 ) — Issuance of warrants in connection with convertible promissory notes (106,087 ) — Issuance of put options in connection with convertible promissory notes — (101,222 ) Income included in net income: Income due to change in fair value 1,842,557 — Balance of liability at December 31, 2013 $ (1,564,941 ) (101,222 ) Issuance of warrants in connection with convertible promissory notes (5,331,175 ) — Issuance of put and call options in connection with convertible promissory notes — (1,667,136 ) Transfer to additional paid-in capital upon completion of initial public offering 7,118,056 3,449,866 Loss included in net loss: Loss due to change in fair value (221,940 ) (1,681,508 ) Balance of liability at December 31, 2014 $ — —

Cash and Cash Equivalents (Tabl

Cash and Cash Equivalents (Tables)	12 Months Ended
	Dec. 31, 2015
Cash And Cash Equivalents [Abstract]
Summary of Cash and Cash Equivalents	The following is a summary of cash and cash equivalents and their fair values at: Amortized Unrealized Unrealized Fair market cost gains losses value December 31, 2014 Cash $ 16,792,286 $ — $ — $ 16,792,286 Money market funds 20,173 — — 20,173 Total at December 31, 2014 $ 16,812,459 $ — $ — $ 16,812,459 December 31, 2015 Cash $ 9,900,722 $ — $ — $ 9,900,722 Total at December 31, 2015 $ 9,900,722 $ — $ — $ 9,900,722

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2015
Property Plant And Equipment [Abstract]
Summary of Components of Property and Equipment	Property and equipment consist of the following at: Year ended December 31, 2015 2014 Furniture and fixtures 195,420 212,471 Leasehold improvements 7,638,683 7,617,934 Laboratory equipment 1,924,581 3,819,740 Computer and office equipment 250,324 617,264 10,009,008 12,267,409 Less accumulated depreciation (9,799,287 ) (11,811,641 ) 209,721 455,768

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2015
Summary of Outstanding Common Stock Options and Warrants Issued to Employees, Directors, and Consultants	The following table summarizes common stock option and warrant activities for common stock options and warrants issued to employees, directors, and consultants: Weighted Weighted average Number of average remaining common stock exercise contractual options price term (years) Outstanding at December 31, 2012 376,880 7.87 Exercised (382 ) 4.73 Canceled (147,004 ) 7.82 Outstanding at December 31, 2013 229,494 7.90 Granted 7,279 15.10 Exercised (8,009 ) 4.73 Canceled (9,584 ) 5.86 Outstanding at December 31, 2014 219,180 8.35 Granted 79,603 7.27 Canceled (49,784 ) 9.08 Outstanding at December 31, 2015 248,999 7.86 4.2 Exercisable at December 31, 2015 190,659 8.08 2.7
Exercisable and Outstanding Common Stock Options and Warrants Issued to Employees, Directors, and Consultants by Exercise Prices	The following table summarizes information about stock options issued to employees, directors, and consultants that is outstanding at December 31, 2015: Common stock options Common stock options outstanding exercisable Weighted average Weighted remaining average Number contractual Number exercise Exercise price outstanding life (years) exercisable price $ 2.56 6,788 9.53 — $ 2.56 4.73 51,396 0.37 51,396 $ 4.73 5.04 3,995 1.34 3,995 5.04 5.98 59,402 2.17 59,402 5.98 6.93 14,881 3.25 14,881 6.93 7.71 54,246 9.02 2,694 7.71 8.52 3,461 3.75 3,461 8.52 10.07 1,573 5.21 1,573 10.07 12.56 38,369 4.65 38,369 12.56 18.24 14,888 6.24 14,888 18.24 248,999 190,659
Summary of Preferred Stock Warrants Outstanding, Fair Value of Warrants and Assumptions Used to Estimate Fair Value	The Company had the following preferred stock warrants that vested upon issuance outstanding as of December 31, 2013 and July 8, 2014 (the close of the IPO). Also included below are the Black-Scholes assumptions used to estimate the fair value of the warrants: Issuance of 2004 Convertible 2006 Convertible Series D Total Total Financing promissory Financing promissory preferred Long- Short- Warrants issued in connection with agreement notes agreement notes stock term term Issue date March June April May May Redeemable, convertible preferred stock underlying the warrant Series A Series B Series B Series C Series C Number of warrants 22,000 411,060 179,372 622,826 2,076,125 Exercise price $ 1.25 1.338 1.338 1.445 1.445 Black-Scholes assumptions as of December 31, 2012 Remaining term (years) 1.2 2.5 3.3 6.4 6.4 Estimated volatility 83 % 86.5 % 85.5 % 92 % 92 % Risk-free interest rate 0.16 % 0.31 % 0.35 % 0.92 % 0.92 % Number of warrants remaining 22,000 411,060 179,372 620,294 2,076,125 Estimated fair value at December 31, 2012 $ 2,837 100,270 52,680 723,631 2,421,993 3,301,411 — Black-Scholes assumptions as of December 31, 2013 Remaining term (years) 0.2 1.5 2.3 5.4 5.4 Estimated volatility 61 % 66.5 % 84.5 % 97 % 97 % Risk-free interest rate 0.07 % 0.24 % 0.52 % 1.58 % 1.58 % Number of warrants remaining 22,000 411,060 179,372 620,294 2,076,125 Estimated fair value at December 31, 2013 $ 13 28,098 32,735 321,603 1,076,405 1,458,841 13 Black-Scholes assumptions as of at July 8, 2014 (close of IPO) Remaining term (years) 1.0 1.8 4.9 4.9 Estimated volatility 70.5 % 68.5 % 82 % 82 % Risk-free interest rate 0.12 % 0.33 % 1.52 % 1.52 % Number of warrants remaining 411,060 179,372 620,294 2,076,125 Estimated fair value at July 8, 2014 (close of IPO) $ (* ) 1,395 2,539 70,381 235,564 309,879 — (*) This warrant expired unexercised on March 18, 2014
Employees
Summary of Significant Assumptions Used in Black-Scholes Option Pricing Model to Estimate Fair Value of Stock Options Granted to Employees and Non-employees	The Company uses the Black-Scholes option pricing model to estimate the fair value of stock options for employee grants and used the following assumptions to obtain the weighted average grant date fair values: Year Ended December 31, 2015 2014 2013 (a) Risk-free interest rate 1.6% - 1.7% 1.82% — Expected life (in years) 5.5 - 6.0 6.0 — Expected volatility 78.7% - 91.1% 95.7% — (a) There were no stock options granted in 2013.
Non Employees
Summary of Significant Assumptions Used in Black-Scholes Option Pricing Model to Estimate Fair Value of Stock Options Granted to Employees and Non-employees	The Company uses the Black-Scholes option pricing model to estimate the fair value of stock options for nonemployee grants and used the following assumptions to estimate fair value each respective year: Year Ended December 31, 2015 2014 2013 Risk-free interest rate 2.0% - 2.2% 2.8% - 3.0% 1.8% - 2.7% Expected life (in years) 10 10 10 Expected volatility 85.3% -85.7% 85.2% -85.4% 82.6% -85.1%

Deferred Revenue (Tables)

Deferred Revenue (Tables)	12 Months Ended
	Dec. 31, 2015
Deferred Revenue Disclosure [Abstract]
Components of Deferred Revenue	Deferred revenue consisted of the following as of: Year ended December 31, 2015 2014 Celgene $ 7,543,927 10,751,120 Gilead 27,457 32,949 Total deferred revenue 7,571,384 10,784,069 Less: current portion (3,450,582 ) (3,340,571 ) Deferred revenue, long-term $ 4,120,802 7,443,498

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2015
Commitments And Contingencies Disclosure [Abstract]
Future Minimum Lease Payments	Including the lease amendment, future minimum lease payments under the Company’s noncancelable operating leases are as follows as of December 31, 2015: 2016 $ 609,339 2017 627,702 2018 646,475 2019 162,798 $ 2,046,314

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation	A reconciliation of income taxes at the statutory federal income tax rate to net income taxes included in the accompanying statements of operations is as follows: Year Ended December 31, 2015 2014 2013 U.S. federal income tax expense at the statutory rate (34.0 ) % (34.0 ) % 34.0 % State income taxes, net of federal taxes (3.8 ) (1.4 ) 4.1 Available research credits (6.0 ) (2.4 ) (9.3 ) Effect of permanent differences 1.8 22.2 (5.8 ) Change in valuation allowance 42.0 15.6 (21.8 ) Total — % — % 1.2 %
Schedule of Deferred Tax Assets and Liabilities	The components of the Company’s deferred tax assets and liabilities are as follows: December 31, 2015 2014 Accrued benefits $ 87,290 93,380 Net operating loss carryforwards 46,660,006 44,142,487 Research credit carryforwards 7,195,372 7,045,830 Deferred revenue 2,839,379 4,138,236 Depreciation of property and equipment 1,128,671 1,351,186 Other 131,766 111,250 Total deferred tax assets 58,042,484 56,882,369 Valuation allowance (58,042,484 ) (56,882,369 ) Deferred tax assets, net of valuation allowance $ — —

Liquidity Risks - Additional In

Liquidity Risks - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Risks And Uncertainties [Abstract]
Accumulated deficit	$ (225,471,645)	$ (222,704,740)
Net income (loss)	(2,766,905)	(16,260,926)	$ 9,476,699
Net cash provided by (used in) operating activities	$ (7,129,697)	$ (10,051,096)	$ 3,931,727

Summary of Significant Accoun28

Summary of Significant Accounting Policies - Additional Information (Details)	Jul. 08, 2014USD ($)$ / sharesshares	Dec. 31, 2013USD ($)	Dec. 31, 2015USD ($)Segment	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)
Summary Of Significant Accounting Policies [Line Items]
Proceeds from issuance of common stock				$ 14,619,859
Liquid instruments maturity period			90 days
Cash equivalents maturity period			90 days
Depreciation and amortization			$ 187,335	295,165	$ 771,280
Security deposit			100,000	100,000
Prepayments of other assets			105,645
Accrued clinical trial holdbacks			$ 0	32,385
Percentage of holdbacks on payments due to entities			5.00%
Unrecognized uncertain tax positions			$ 0	0
Warrants outstanding, fair value	$ 7,118,054			0
Number of operating segment | Segment			1
Research and development expense			$ 4,483,138	$ 7,213,416	$ 10,884,628
National Institute of Allergy and Infectious Diseases
Summary Of Significant Accounting Policies [Line Items]
Receipt of research project grant		$ 4,000,000
Performance and reimbursement period		4 years
Unused portion of the grant			$ 2,000,000
2013 Notes
Summary Of Significant Accounting Policies [Line Items]
Conversion of preferred stock warrants into common stock | shares	51,556
Common Stock to be issued up on exercise of warrants | shares	12,373
2014 Convertible Notes
Summary Of Significant Accounting Policies [Line Items]
Conversion of preferred stock warrants into common stock | shares	1,116,372
Common Stock to be issued up on exercise of warrants | shares	750,000
IPO
Summary Of Significant Accounting Policies [Line Items]
Common stock, shares issued | shares	1,725,000
Common stock, par value | $ / shares	$ 10
Proceeds from issuance of common stock	$ 17,250,000
Conversion of preferred stock to common stock | shares	2,757,825

Summary of Significant Accoun29

Summary of Significant Accounting Policies - Estimated Useful Lives of Property and Equipment (Details)	12 Months Ended
	Dec. 31, 2015
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Property, plant and equipment, useful lives	7 years
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property, plant and equipment, useful lives description	Lesser of useful life or life of the lease
Laboratory Equipment
Property Plant And Equipment [Line Items]
Property, plant and equipment, useful lives	5 years
Computer and Office Equipment
Property Plant And Equipment [Line Items]
Property, plant and equipment, useful lives	3 years

Summary of Significant Accoun30

Summary of Significant Accounting Policies - Schedule of Accrued Liabilities (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Accrued Liabilities And Other Liabilities [Abstract]
Accrued compensation	$ 112,473	$ 578,091
Accrued clinical trial holdbacks	0	32,385
Other	428,314	648,856
Total Accrued Liabilities	$ 540,787	$ 1,259,332

Summary of Significant Accoun31

Summary of Significant Accounting Policies - Schedule of Net Loss Per Share, Basic and Diluted (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Numerator:
Net loss attributable to GlobeImmune, Inc. common stockholders	$ (2,766,905)	$ (23,434,827)	$ (3,408,442)
Denominator:
Weighted-average common shares used in computing net loss per share of common stock - basic and diluted	5,751,574	2,914,690	92,522
Net loss per share of common stock attributable to GlobeImmune, Inc. stockholders - basic and diluted	$ (0.48)	$ (8.04)	$ (36.84)

Summary of Significant Accoun32

Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Details) - shares		12 Months Ended
		Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from the calculation of diluted net loss per share		1,175,813	2,568,454	3,101,297
Convertible Preferred Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from the calculation of diluted net loss per share	[1]		1,428,024	2,757,825
Warrants to Purchase Convertible Preferred Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from the calculation of diluted net loss per share	[1]	926,814	411,303	107,057
Options and Warrants to Purchase Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from the calculation of diluted net loss per share		248,999	219,180	229,494
Convertible Promissory Note
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from the calculation of diluted net loss per share			509,947	6,921
[1]	The convertible preferred stock and convertible preferred stock warrants (common stock warrants after the initial public offering) were computed on an as converted basis using a 31.39-to-one conversion ratio for all periods presented.

Summary of Significant Accoun33

Summary of Significant Accounting Policies - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Assets measured at fair value:
Money market investments (included in cash and cash equivalents)	$ 9,900,722	$ 16,812,459
Fair Value, Measurements, Recurring
Assets measured at fair value:
Money market investments (included in cash and cash equivalents)		20,173
Quoted prices in active markets for identical assets (Level 1) | Fair Value, Measurements, Recurring
Assets measured at fair value:
Money market investments (included in cash and cash equivalents)		$ 20,173

Summary of Significant Accoun34

Summary of Significant Accounting Policies - Reconciliation of Assets and Liabilities Measured at Fair Value Using Significant Unobservable Level 3 Inputs (Details) - USD ($)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Put Options
Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance of liability	$ (101,222)
Issuance of warrants in connection with convertible promissory notes	(1,667,136)	$ (101,222)
Transfer to additional paid-in capital upon completion of initial public offering	3,449,866
Income (loss) due to change in fair value	(1,681,508)
Ending Balance of liability		(101,222)
Warrant
Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance of liability	(1,564,941)	(3,301,411)
Issuance of warrants in connection with convertible promissory notes	(5,331,175)	(106,087)
Transfer to additional paid-in capital upon completion of initial public offering	7,118,056
Income (loss) due to change in fair value	$ (221,940)	1,842,557
Ending Balance of liability		$ (1,564,941)

Cash and Cash Equivalents - Sch

Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Cash And Cash Equivalents [Line Items]
Amortized cost	$ 9,900,722	$ 16,812,459
Fair market value	9,900,722	16,812,459
Cash
Cash And Cash Equivalents [Line Items]
Amortized cost	9,900,722	16,792,286
Fair market value	$ 9,900,722	16,792,286
Money market funds
Cash And Cash Equivalents [Line Items]
Amortized cost		20,173
Fair market value		$ 20,173

Property and Equipment - Summar

Property and Equipment - Summary of Components of Property and Equipment (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 10,009,008	$ 12,267,409
Less accumulated depreciation	(9,799,287)	(11,811,641)
Property and equipment, net	209,721	455,768
Furniture and Fixtures
Property Plant And Equipment [Line Items]
Property and equipment, gross	195,420	212,471
Leasehold Improvements
Property Plant And Equipment [Line Items]
Property and equipment, gross	7,638,683	7,617,934
Laboratory Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	1,924,581	3,819,740
Computer and Office Equipment
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 250,324	$ 617,264

Convertible Notes - Additional

Convertible Notes - Additional Information (Details) - USD ($)	Jul. 08, 2014	Nov. 30, 2013	Feb. 28, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Debt Instrument [Line Items]
Noncash interest expense from amortization of debt discount and amortization of debt issuance costs					$ 3,562,946	$ 9,268
Loss on extinguishment of convertible notes					(4,687,649)
Fair value of warrants issued for debt issuance costs					876,778
2013 Notes
Debt Instrument [Line Items]
Convertible promissory note		$ 391,730
Convertible promissory note , interest rate		8.00%
Debt instrument, expiry period		3 years
Warrant, expiry period		10 years
Price per share of common stock as a percentage IPO price		80.00%
Warrant coverage percentage of notes		30.00%
Fair value of warrants attached to convertible promissory note		$ 106,087
Fair value put option embedded in convertible promissory note		101,222
Noncash interest expense from amortization of debt discount and amortization of debt issuance costs		$ 207,309
Amortization of debt discount					35,749	9,268
Unamortized balance of debt discount						$ 198,041
Conversion of preferred stock warrants into common stock	51,556
Conversion price per share	$ 8
Debt instrument, convertible, carrying amount of debt	$ 352,986
Accrued interest	20,718
Loss on extinguishment of convertible notes	$ (162,574)
Common Stock to be issued up on exercise of warrants	12,373
Class of warrant or right, exercise price of warrants or rights	$ 10
2014 Convertible Notes
Debt Instrument [Line Items]
Convertible promissory note , interest rate			10.00%
Price per share of common stock as a percentage IPO price			70.00%
Warrant coverage percentage of notes				100.00%
Fair value of warrants attached to convertible promissory note			$ 4,454,397
Noncash interest expense from amortization of debt discount and amortization of debt issuance costs			6,121,533
Amortization of debt discount					2,682,285
Conversion of preferred stock warrants into common stock	1,116,372
Conversion price per share	$ 7
Debt instrument, convertible, carrying amount of debt	$ 6,638,645
Accrued interest	314,210
Loss on extinguishment of convertible notes	$ (4,525,075)
Common Stock to be issued up on exercise of warrants	750,000
Class of warrant or right, exercise price of warrants or rights	$ 10
Convertible notes payable			$ 7,500,000
Debt instrument, maturity date			Jan. 31, 2015
Debt issuance costs			$ 1,928,265
Fair value of warrants issued for debt issuance costs			876,778
Amortization of debt issuance costs					$ 844,912
2014 Convertible Notes | Exchange Traded Options
Debt Instrument [Line Items]
Fair value put option embedded in convertible promissory note			$ 1,667,136
2014 Convertible Notes | Equity
Debt Instrument [Line Items]
Warrant, expiry period				5 years

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Details) - USD ($)	Jul. 08, 2014	Feb. 28, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Apr. 30, 2014
Class Of Stock [Line Items]
Proceeds from issuance of common stock				$ 14,619,859
Preferred stock, shares authorized	5,000,000		5,000,000	5,000,000
Preferred stock, par value	$ 0.001		$ 0.001	$ 0.001
Preferred stock, shares issued			0	0
Preferred stock, shares outstanding			0	0
Forfeiture rate			57.80%	13.70%
Net income (loss)			$ (2,766,905)	$ (16,260,926)	$ 9,476,699
Research and development expense			4,483,138	7,213,416	10,884,628
General and administrative			$ 4,554,165	4,276,918	3,174,769
Warrant extended term period			5 years
Fair value of warrants issued for debt issuance costs				$ 876,778
Common stock, shares authorized	100,000,000		100,000,000	100,000,000
Common stock, par value	$ 0.001		$ 0.001	$ 0.001
Common stock, shares issued			5,751,574	5,751,574
Common stock, shares outstanding			5,751,574	5,751,574
Common stock issuable upon exercise of outstanding warrants			926,746
Warrant
Class Of Stock [Line Items]
Fair value assumptions, warrants	$ 104,055
Expected volatility	91.00%
Risk-free interest rate	2.60%
Expected term	9 years 4 months 24 days
2014 EIP
Class Of Stock [Line Items]
Share of common stock reserved for issuance under plans, increase description			EIP will automatically increase on January 1 of each year, starting on January 1, 2015 and continuing through January 1, 2024, by the lesser of 4% of the total number shares of our common stock outstanding on the immediately preceding December 31, or a lesser amount of shares determined by our Board of Directors.
Percentage increase in common stock outstanding			4.00%
Options to Purchase Common Stock
Class Of Stock [Line Items]
Weighted average grant date fair value of options granted			$ 5.55	$ 11.66
Total grant date fair value of options vested			$ 83,119	$ 72,095	193,828
Difference between the aggregate exercise price and aggregate fair value price				60,940	1,560
Intrinsic value of options outstanding			8,205	286,299
Intrinsic value of options exercisable			0	286,299
Company had unrecognized stock based compensation			$ 217,191	$ 79,145
Non-vested stock options, estimated weighted average period			3 years	2 years 2 months 12 days
Net income (loss)			$ 151,814	$ 48,878	209,715
Research and development expense			3,867	8,919	47,082
General and administrative			$ 147,947	39,959	$ 162,633
Options to Purchase Common Stock | 2014 EIP
Class Of Stock [Line Items]
Share of common stock reserved for issuance under plans						393,358
Share of common stock reserved for issuance under plans			801,556
Shares authorized			1,071,642
Options to Purchase Common Stock | 2014 EIP | Evergreen Provision
Class Of Stock [Line Items]
Increase in shares of common stock			230,062
Options to Purchase Common Stock | 2014 EIP | Evergreen Provision | Maximum
Class Of Stock [Line Items]
Share of common stock reserved for issuance under plans			1,301,704
Options to Purchase Common Stock | 2014 ESPP
Class Of Stock [Line Items]
Share of common stock reserved for issuance under plans, increase description			ESPP will automatically increase on January 1 of each year, starting on January 1, 2015 and continuing through January 1, 2024, by the least of (i) 1% of the total number of shares of our common stock outstanding on the immediately preceding December 31; (ii) 402,326 shares of common stock; or (iii) a lesser amount of shares determined by our Board of Directors.
Percentage increase in common stock outstanding			1.00%
Share of common stock reserved for issuance under plans						201,163
Increase in shares of common stock			402,326
Options to Purchase Common Stock | 2014 ESPP | Evergreen Provision
Class Of Stock [Line Items]
Increase in shares of common stock			57,515
Options to Purchase Common Stock | 2014 ESPP | Evergreen Provision | Maximum
Class Of Stock [Line Items]
Share of common stock reserved for issuance under plans			316,193
2013 Notes
Class Of Stock [Line Items]
Conversion of preferred stock warrants into common stock	51,556
Common Stock to be issued up on exercise of warrants	12,373
Class of warrant or right, exercise price of warrants or rights	$ 10
2013 Notes | Warrant
Class Of Stock [Line Items]
Common Stock to be issued up on exercise of warrants	12,373
Class of warrant or right, exercise price of warrants or rights	$ 10
2014 Convertible Notes
Class Of Stock [Line Items]
Conversion of preferred stock warrants into common stock	1,116,372
Common Stock to be issued up on exercise of warrants	750,000
Class of warrant or right, exercise price of warrants or rights	$ 10
Convertible notes payable		$ 7,500,000
Fair value of warrants issued for debt issuance costs		$ 876,778
2014 Notes | Warrant
Class Of Stock [Line Items]
Fair value assumptions, warrants				4,454,397
Convertible notes payable				7,500,000
IPO
Class Of Stock [Line Items]
Common stock, shares issued	1,725,000
Common stock, par value	$ 10
Proceeds from issuance of common stock	$ 17,250,000
Conversion of preferred stock to common stock	2,757,825
Private placement
Class Of Stock [Line Items]
Fair value assumptions, warrants				$ 750,000
Risk free interest rate				10.00%
Private placement | 2014 Convertible Notes
Class Of Stock [Line Items]
Common Stock to be issued up on exercise of warrants	59,998
Warrant holders
Class Of Stock [Line Items]
Fair value assumptions, warrants				$ 750,000
Risk free interest rate				10.00%

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Significant Assumptions Used in Black-Scholes Option Pricing Model to Estimate Fair Value of Stock Options Granted to Employees (Details) - Employee Stock Option	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate, minimum	1.60%
Risk-free interest rate, maximum	1.70%
Risk-free interest rate		1.82%
Expected life (in years)		6 years
Expected volatility		95.70%
Expected volatility, minimum	78.70%
Expected volatility, maximum	91.10%
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected life (in years)	5 years 6 months
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected life (in years)	6 years

Stockholders' Equity - Summar40

Stockholders' Equity - Summary of Significant Assumptions Used in Black-Scholes Option Pricing Model to Estimate Fair Value of Stock Options Granted to Non-employees (Details) - Nonemployee Stock Option	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate, minimum	2.00%	2.80%	1.80%
Risk-free interest rate, maximum	2.20%	3.00%	2.70%
Expected life (in years)	10 years	10 years	10 years
Expected volatility, minimum	85.30%	85.20%	82.60%
Expected volatility, maximum	85.70%	85.40%	85.10%

Stockholders' Equity - Summar41

Stockholders' Equity - Summary of Outstanding Common Stock Options and Warrants Issued to Employees, Directors, and Consultants (Details) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Equity [Abstract]
Number of common stock options, Outstanding at beginning of period	219,180	229,494	376,880
Number of common stock options, Granted	79,603	7,279
Number of common stock options, Exercised		(8,009)	(382)
Number of common stock options, Canceled	(49,784)	(9,584)	(147,004)
Number of common stock options, Outstanding at end of period	248,999	219,180	229,494
Number of common stock options, Exercisable at end of period	190,659
Weighted average exercise price, Outstanding at beginning of period	$ 8.35	$ 7.90	$ 7.87
Weighted average exercise price, Granted	7.27	15.10
Weighted average exercise price, Exercised		4.73	4.73
Weighted average exercise price, Canceled	9.08	5.86	7.82
Weighted average exercise price, Outstanding at end of period	7.86	$ 8.35	$ 7.90
Weighted average exercise price, Exercisable at end of period	$ 8.08
Weighted average remaining contractual term (years), Outstanding at end of period	4 years 2 months 12 days
Weighted average remaining contractual term (years), Exercisable at end of period	2 years 8 months 12 days

Stockholders' Equity - Exercisa

Stockholders' Equity - Exercisable and Outstanding Stock Options and Warrants Issued to Employees, Directors, and Consultants by Exercise Prices (Details) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock options outstanding	248,999	219,180	229,494	376,880
Common stock options outstanding, Weighted average remaining contractual life (years)	4 years 2 months 12 days
Common stock options exercisable	190,659
Common stock options exercisable, Weighted average exercise price	$ 8.08
2.56
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price	$ 2.56
Common stock options outstanding	6,788
Common stock options outstanding, Weighted average remaining contractual life (years)	9 years 6 months 11 days
Common stock options exercisable, Weighted average exercise price	$ 2.56
4.73
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price	$ 4.73
Common stock options outstanding	51,396
Common stock options outstanding, Weighted average remaining contractual life (years)	4 months 13 days
Common stock options exercisable	51,396
Common stock options exercisable, Weighted average exercise price	$ 4.73
5.04
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price	$ 5.04
Common stock options outstanding	3,995
Common stock options outstanding, Weighted average remaining contractual life (years)	1 year 4 months 2 days
Common stock options exercisable	3,995
Common stock options exercisable, Weighted average exercise price	$ 5.04
5.98
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price	$ 5.98
Common stock options outstanding	59,402
Common stock options outstanding, Weighted average remaining contractual life (years)	2 years 2 months 1 day
Common stock options exercisable	59,402
Common stock options exercisable, Weighted average exercise price	$ 5.98
6.93
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price	$ 6.93
Common stock options outstanding	14,881
Common stock options outstanding, Weighted average remaining contractual life (years)	3 years 3 months
Common stock options exercisable	14,881
Common stock options exercisable, Weighted average exercise price	$ 6.93
7.71
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price	$ 7.71
Common stock options outstanding	54,246
Common stock options outstanding, Weighted average remaining contractual life (years)	9 years 7 days
Common stock options exercisable	2,694
Common stock options exercisable, Weighted average exercise price	$ 7.71
8.52
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price	$ 8.52
Common stock options outstanding	3,461
Common stock options outstanding, Weighted average remaining contractual life (years)	3 years 9 months
Common stock options exercisable	3,461
Common stock options exercisable, Weighted average exercise price	$ 8.52
10.07
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price	$ 10.07
Common stock options outstanding	1,573
Common stock options outstanding, Weighted average remaining contractual life (years)	5 years 2 months 16 days
Common stock options exercisable	1,573
Common stock options exercisable, Weighted average exercise price	$ 10.07
12.56
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price	$ 12.56
Common stock options outstanding	38,369
Common stock options outstanding, Weighted average remaining contractual life (years)	4 years 7 months 24 days
Common stock options exercisable	38,369
Common stock options exercisable, Weighted average exercise price	$ 12.56
18.24
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Exercise price	$ 18.24
Common stock options outstanding	14,888
Common stock options outstanding, Weighted average remaining contractual life (years)	6 years 2 months 27 days
Common stock options exercisable	14,888
Common stock options exercisable, Weighted average exercise price	$ 18.24

Stockholders' Equity - Summar43

Stockholders' Equity - Summary of Preferred Stock Warrants Outstanding, Fair Value of Warrants And Assumptions Used to Estimate Fair Value (Details) - Black-Scholes Assumptions - USD ($)	Jul. 08, 2014	Dec. 31, 2015	Dec. 31, 2013	Dec. 31, 2012
Total Long-term
Black-Scholes assumptions
Estimated fair value of vested warrants	$ 309,879		$ 1,458,841	$ 3,301,411
Total Short-term
Black-Scholes assumptions
Estimated fair value of vested warrants			$ 13
Warrants Issued With 2004 Financing Agreement
Class Of Stock [Line Items]
Issue date		2004-03
Redeemable and convertible preferred stock underlying the warrant		Series A
Number of warrants issued		22,000
Class of warrant or right, exercise price of warrants or rights		$ 1.25
Black-Scholes assumptions
Remaining term (years)			2 months 12 days	1 year 2 months 12 days
Estimated volatility			61.00%	83.00%
Risk-free interest rate			0.07%	0.16%
Number of warrants remaining outstanding			22,000	22,000
Estimated fair value of vested warrants			$ 13	$ 2,837
Warrants Issued With 2005 Convertible Promissory Notes
Class Of Stock [Line Items]
Issue date		2005-06
Redeemable and convertible preferred stock underlying the warrant		Series B
Number of warrants issued		411,060
Class of warrant or right, exercise price of warrants or rights		$ 1.338
Black-Scholes assumptions
Remaining term (years)	1 year		1 year 6 months	2 years 6 months
Estimated volatility	70.50%		66.50%	86.50%
Risk-free interest rate	0.12%		0.24%	0.31%
Number of warrants remaining outstanding	411,060		411,060	411,060
Estimated fair value of vested warrants	$ 1,395		$ 28,098	$ 100,270
Warrants Issued With 2006 Financing Agreement
Class Of Stock [Line Items]
Issue date		2006-04
Redeemable and convertible preferred stock underlying the warrant		Series B
Number of warrants issued		179,372
Class of warrant or right, exercise price of warrants or rights		$ 1.338
Black-Scholes assumptions
Remaining term (years)	1 year 9 months 18 days		2 years 3 months 18 days	3 years 3 months 18 days
Estimated volatility	68.50%		84.50%	85.50%
Risk-free interest rate	0.33%		0.52%	0.35%
Number of warrants remaining outstanding	179,372		179,372	179,372
Estimated fair value of vested warrants	$ 2,539		$ 32,735	$ 52,680
Warrants Issued With 2009 Convertible Promissory Notes
Class Of Stock [Line Items]
Issue date		2009-05
Redeemable and convertible preferred stock underlying the warrant		Series C
Number of warrants issued		622,826
Class of warrant or right, exercise price of warrants or rights		$ 1.445
Black-Scholes assumptions
Remaining term (years)	4 years 10 months 24 days		5 years 4 months 24 days	6 years 4 months 24 days
Estimated volatility	82.00%		97.00%	92.00%
Risk-free interest rate	1.52%		1.58%	0.92%
Number of warrants remaining outstanding	620,294		620,294	620,294
Estimated fair value of vested warrants	$ 70,381		$ 321,603	$ 723,631
Warrants Issued With 2009 Issuance of Series D Preferred Stock
Class Of Stock [Line Items]
Issue date		2009-05
Redeemable and convertible preferred stock underlying the warrant		Series C
Number of warrants issued		2,076,125
Class of warrant or right, exercise price of warrants or rights		$ 1.445
Black-Scholes assumptions
Remaining term (years)	4 years 10 months 24 days		5 years 4 months 24 days	6 years 4 months 24 days
Estimated volatility	82.00%		97.00%	92.00%
Risk-free interest rate	1.52%		1.58%	0.92%
Number of warrants remaining outstanding	2,076,125		2,076,125	2,076,125
Estimated fair value of vested warrants	$ 235,564		$ 1,076,405	$ 2,421,993

Deferred Revenue - Components o

Deferred Revenue - Components of Deferred Revenue (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Deferred Revenue Arrangement [Line Items]
Total deferred revenue	$ 7,571,384	$ 10,784,069
Less: current portion	(3,450,582)	(3,340,571)
Deferred revenue, long-term	4,120,802	7,443,498
Celgene
Deferred Revenue Arrangement [Line Items]
Total deferred revenue	7,543,927	10,751,120
Gilead
Deferred Revenue Arrangement [Line Items]
Total deferred revenue	$ 27,457	$ 32,949

Deferred Revenue - Additional I

Deferred Revenue - Additional Information (Details)	1 Months Ended						3 Months Ended		12 Months Ended				36 Months Ended
	Jul. 31, 2015USD ($)	Jul. 31, 2013USD ($)	Apr. 30, 2012USD ($)	Nov. 30, 2011USD ($)	Oct. 31, 2011USD ($)	May. 31, 2009USD ($)	Sep. 30, 2015USD ($)	Dec. 31, 2013USD ($)	Dec. 31, 2015USD ($)Product	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)	Dec. 31, 2012USD ($)	Apr. 30, 2012USD ($)
Deferred Revenue Arrangement [Line Items]
Collaboration license and services									$ 6,169,634	$ 4,426,561	$ 16,350,132
Costs of collaboration license and services									2,359,961	3,452,392	5,856,013
Milestones											3,000,000
Remaining balance to be recognized under license agreement									7,571,384	10,784,069
Manufacturing services									288,099	1,539,820	3,168,237
Costs of manufacturing services									$ 288,099	1,539,820	3,168,237
Celgene
Deferred Revenue Arrangement [Line Items]
Collaboration and Option agreement date									May 31, 2009
Number of oncology products | Product									4
Upfront payment received		$ 9,000,000											$ 31,300,000
Initial nonrefundable payment received			$ 300,000		$ 1,000,000	$ 30,000,000
Unamortized amount									$ 7,377,906	10,656,976
Estimated selling price on license agreement	$ 1,900,000	9,000,000
Costs of collaboration license and services									2,046,970	2,563,409	2,515,055
Remaining balance to be recognized under license agreement									7,543,927	10,751,120
Celgene | License
Deferred Revenue Arrangement [Line Items]
License and service revenue recognized									1,828,124	138,975	8,766,881
Celgene | Maximum
Deferred Revenue Arrangement [Line Items]
Net sales milestones amount to be recognized									60,000,000
Celgene | Development And Regulatory Milestones | Maximum
Deferred Revenue Arrangement [Line Items]
Net sales milestones amount to be recognized									101,000,000
Celgene | GI-6200
Deferred Revenue Arrangement [Line Items]
Upfront payment received	1,900,000
Celgene | GI-6200 | Undelivered Items
Deferred Revenue Arrangement [Line Items]
Net sales milestones amount to be recognized	$ 71,876								71,876
Celgene | GI-6200 | License
Deferred Revenue Arrangement [Line Items]
Collaboration license and services							$ 1,828,124
Celgene | GI-6200 | Development And Regulatory Milestones
Deferred Revenue Arrangement [Line Items]
Net sales milestones amount to be recognized									60,000,000
Celgene | GI-6100 | Maximum
Deferred Revenue Arrangement [Line Items]
Net sales milestones amount to be recognized									60,000,000
Celgene | GI-6100 | Development And Regulatory Milestones
Deferred Revenue Arrangement [Line Items]
Net sales milestones amount to be recognized									85,000,000
Celgene | GI-6300 | Undelivered Items
Deferred Revenue Arrangement [Line Items]
Net sales milestones amount to be recognized		$ 233,119							94,144	94,144
Celgene | GI-6300 | License
Deferred Revenue Arrangement [Line Items]
Collaboration license and services								$ 8,766,881
Celgene | GI-6300 | Development And Regulatory Milestones
Deferred Revenue Arrangement [Line Items]
Net sales milestones amount to be recognized									85,000,000
Celgene | GI-6300 or GI-6200 | Maximum
Deferred Revenue Arrangement [Line Items]
Net sales milestones amount to be recognized									60,000,000
Celgene | Research and Development Services
Deferred Revenue Arrangement [Line Items]
License and service revenue recognized									3,279,069	3,279,069	3,307,338
Gilead
Deferred Revenue Arrangement [Line Items]
Upfront payment received				$ 10,000,000
Costs of collaboration license and services									312,991	817,103	3,340,958
Milestones											3,000,000	$ 2,000,000
Remaining balance to be recognized under license agreement									27,457	32,949
Manufacturing services									288,099	1,539,820	3,168,237
Costs of manufacturing services									288,099	1,539,820	3,168,237
Gilead | License
Deferred Revenue Arrangement [Line Items]
License and service revenue recognized									5,492	$ 221,392	$ 4,039,538
Gilead | Maximum
Deferred Revenue Arrangement [Line Items]
Net sales milestones amount to be recognized									40,000,000
Gilead | Development And Regulatory Milestones | Maximum
Deferred Revenue Arrangement [Line Items]
Net sales milestones amount to be recognized									$ 130,000,000

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - USD ($)	1 Months Ended	12 Months Ended
	Apr. 30, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Commitments And Contingencies [Line Items]
Royalty advances		$ 500,000
Lease agreement amendment extended term	5 years
Rental Expense		614,349	$ 598,315	$ 448,664
University of Colorado
Commitments And Contingencies [Line Items]
Development milestone payments		150,000
Milestone payment due		$ 162,335	5,000	450,000
National Institutes Of Health License
Commitments And Contingencies [Line Items]
License termination notice period		60 days
Royalty payment		$ 300,000	$ 300,000	$ 300,000
National Institutes Of Health License | Maximum
Commitments And Contingencies [Line Items]
Annual royalty payment		300,000
National Institutes of Health MUC1 Agreement
Commitments And Contingencies [Line Items]
Royalty advances		500,000
National Institutes of Health VirusPlus Agreement
Commitments And Contingencies [Line Items]
Royalty advances		500,000
National Institutes of Health CEA Agreement
Commitments And Contingencies [Line Items]
Royalty advances		745,000
National Institutes of Health Brachyury Agreement
Commitments And Contingencies [Line Items]
Royalty advances		$ 800,000

Commitment and Contingencies -

Commitment and Contingencies - Schedule of Future Minimum Rental Payments for Operating Leases (Details)	Dec. 31, 2015USD ($)
Leases Operating [Abstract]
2,016	$ 609,339
2,017	627,702
2,018	646,475
2,019	162,798
Total	$ 2,046,314

Benefit Plan - Additional Infor

Benefit Plan - Additional Information (Details)	12 Months Ended
	Dec. 31, 2015
Compensation And Retirement Disclosure [Abstract]
Employees Contribution Plan	60.00%

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Taxes [Line Items]
Federal income tax provision or benefit	$ 0	$ 0
Current state tax provision			$ 115,765
Increase in valuation allowance	1,160,115	2,540,162
Federal and state net operating loss carryforwards	122,800,000
Federal research credit carryforwards	7,200,000
Uncertain tax positions, accrued interest or penalties	$ 0	$ 0
Minimum
Income Taxes [Line Items]
Federal and state net operating loss carryforwards expire year	2,023
Federal research credit carryforwards expire year	2,023
Maximum
Income Taxes [Line Items]
Federal and state net operating loss carryforwards expire year	2,035
Federal research credit carryforwards expire year	2,035

Income Taxes - Schedule of Effe

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Effective Income Tax Rate Reconciliation, Percent [Abstract]
U.S. federal income tax expense at the statutory rate	(34.00%)	(34.00%)	34.00%
State income taxes, net of federal taxes	(3.80%)	(1.40%)	4.10%
Available research credits	(6.00%)	(2.40%)	(9.30%)
Effect of permanent differences	1.80%	22.20%	(5.80%)
Change in valuation allowance	42.00%	15.60%	(21.80%)
Total	0.00%	0.00%	1.20%

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Components of Deferred Tax Assets [Abstract]
Accrued benefits	$ 87,290	$ 93,380
Net operating loss carryforwards	46,660,006	44,142,487
Research credit carryforwards	7,195,372	7,045,830
Deferred revenue	2,839,379	4,138,236
Depreciation of property and equipment	1,128,671	1,351,186
Other	131,766	111,250
Total deferred tax assets	58,042,484	56,882,369
Valuation allowance	(58,042,484)	(56,882,369)
Deferred tax assets, net of valuation allowance	$ 0	$ 0